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1,4-butanediol (1,4-BD) See gamma-hydroxybutrate
2C series phenylamines Derivatives of the phenethylamine class of drugs with hallucinogenic properties
abstinence Refraining from licit and/or illicit drug use
acute effect Effects that develops rapidly following ingestion of a drug or substance as a result of 
short term exposure
alcoholic cardiomyopathy A diffuse disorder of the heart muscle seen in individuals with a history of hazardous 
alcohol use. Common symptoms include shortness of breath on exertion and on lying 
down, palpitations, swollen ankles (oedema), and abdominal distention  
alcoholic cerebellar degeneration Neurological complication characterised by unsteadiness and lack of coordination 
(cerebellar ataxia) predominantly affecting the lower extremities
alcoholic gastritis Inflammation of the mucosal lining of the stomach caused by alcohol
alcoholic hepatitis A disorder of the liver characterised by liver cell death and inflammation following 
chronic consumption of hazardous levels of alcohol
alcoholic pancreatitis A disorder characterised by inflammation and destruction of the pancreas, and 
associated with long-term heavy alcohol consumption
amotivational syndrome A constellation of features thought to be associated with substance use, principally 
cannabis use. Features include apathy, loss of effectiveness, diminished capacity to carry 
out complex or long-term plans, low tolerance for frustration, impaired concentration 
and difficulty in following routines
amphetamine One of a class of sympathomimetic amines with powerful stimulant action on the 
central nervous system. The class includes amphetamine, dexamphetamine and 
methamphetamine
amphetamine psychosis A disorder characterised by paranoid delusions, frequently accompanied by 
hallucinations, hyperactivity and mood swings. Develops during or shortly after repeated 
use of moderate or high doses of amphetamine
amyl nitrite See nitrites 
anabolic agents Drugs that are used for their purported muscle-building (anabolic) effects, including 
anabolic-androgenic steroids and other agents with similar anabolic effects
anabolic-androgenic steroids (AAS) A class of drugs with both muscle-building (anabolic) and masculinising (androgenic) 
effects
analgesic A substance that reduces pain. Analgesics may or may not have psychoactive properties
anorectic Causing loss of appetite
anxiolytics Anti-anxiety drugs
arrhythmias A disorder of the heart rate or rhythm, such as beating too fast (tachycardia), too slow 
(bradycardia), or irregularly. There are various types of arrhythmias depending on where 
problems occur along the heart's electrical conduction system
barbiturate A group of central nervous system depressant drugs
benzodiazepine A group of structurally related drugs used mainly as sedatives/hypnotics
blackout A period of memory loss during which there is little recall of activities; not associated 
with loss of consciousness
blood alcohol level The concentration of alcohol present in blood
butyl nitrite See nitrites
caffeine A mild central nervous system stimulant, vasodilator and diuretic
cannabis Denotes psychoactive preparations of the marijuana (hemp) plant, Cannabis sativa
chronic effect Effects arising as a consequence of repeated or long term exposure to a drug or 
substance
clenbuterol An adrenergic stimulant with short-term effects similar to amphetamine. May be used 
alone or in combination with other substances to promote the growth of skeletal muscle 
(anabolic effects) and to reduce body fat (catabolic effects)
clonazepam See benzodiazepines
Health harms of drugs
7Health harms of drugs
CNS stimulants A loosely defined group of drugs that tend to increase behavioural alertness, agitation, 
or excitation
cocaine An alkaloid obtained from coca leaves or synthesised from ecgonine or its derivatives. A 
powerful central nervous system stimulant
cocaine powder Cocaine hydrochloride, a water soluble salt
codeine containing products Widely available as analgesic products containing codeine with aspirin, paracetamol 
or ibuprofen. These products may contain other ingredients such as caffeine. Cough 
medicines containing codeine and other ingredients are also available
convulsion A seizure-like event characterised by loss of consciousness and muscular rigidity, 
followed by jerking of the limbs and trunk
crack/rock cocaine A highly pure form of the freebase of cocaine
cross-tolerance The development of tolerance to a substance, to which the individual has not previously 
been exposed, as result of acute or chronic intake of another substance
delirium An acute organic cerebral syndrome characterised by concurrent disturbances of 
consciousness, attention, perception, orientation, thinking, memory, psychomotor 
behaviour, emotion and the sleep-wake cycle. An alcohol-induced withdrawal syndrome 
with delirium is known as delirium tremens
delirium tremens Withdrawal syndrome with delirium; an acute psychotic state occurring during the 
withdrawal phase in people with alcohol dependence. Characterised by confusion, 
disorientation, paranoid ideation, delusions, illusions, hallucinations, restlessness, 
distractibility, tremor, sweating, tachycardia and hypertension
dependence A cluster of symptoms that indicate a person has impaired control over their 
psychoactive substance use, e.g continuing use despite adverse consequences
dependence potential The propensity of a substance to give rise to dependence
dependence syndrome A cluster of behavioural, cognitive and physiological phenomena that may develop after 
repeated substance use
depressant Any drug that suppresses, inhibits, or decreases some aspect of central nervous system 
activity
dexamphetamine A central nervous system stimulant and sympathomimetic. Has been used in the 
treatment of narcolepsy and attention-deficit disorders and hyperactivity in children
dextromethorphan Developed as a non-opioid cough suppressant. The main metabolite of the drug, 
dextrorphan, is thought to be largely responsible for the abuse potential of the drug. At 
high doses exerts similar actions to phencyclidine
diazepam See benzodiazepines
disinhibition A state of release from internal constraints on an individual’s behaviour
dissociative anaesthetic Compound, such as phencyclidine or ketamine, which produces an anaesthetic effect 
characterised by a feeling of being detached from the physical self
ecstasy See MDMA
fatty liver disease Accumulation of fat in the liver following exposure to hazardous levels of alcohol
flashbacks A spontaneous recurrence of visual distortions, physical symptoms, loss of ego 
boundaries, or intense emotions that occurred during past use of hallucinogens and 
dissociative drugs
foetal alcohol spectrum disorder A combination of mental and physical disabilities present at birth caused by maternal 
alcohol consumption during pregnancy
gamma-butyrolactone (GBL) See GHB
gamma-hydroxybutyrate (GHB) A naturally occurring endogenous compound. Originally synthesised for use as 
an anaesthetic it is used recreationally for its sedative and anaesthetic effects. The 
precursors of GHB, gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) are rapidly 
broken down in vivo to GHB  and may also be used recreationally
growth hormone May be used alone or in combination with other substances to induce muscle-building 
(anabolic) effects, reduce muscle cell breakdown and reduce body fat
hallucinations Hallucinations involve sensing things while awake that appear to be real, but instead 
have been created by the mind
hallucinogen A chemical agent that induces alterations in perception, thinking and feeling
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heroin A simple derivative of morphine. Heroin is the most widely used illicit opioid because of 
its potency, availability, solubility in water and speed with which it crosses the blood-
brain barrier
human (and non-human) chorionic 
gonadotropin
Used to complement a cycle of anabolic-androgenic steroids. Their primary use is as part 
of the post-cycle recovery, to 'kickstart' natural testosterone production following a long 
cycle of AAS
illicit drug A psychoactive substance, the production, sale, possession or use of which is prohibited
isobutyl nitrite See nitrites
ketamine A dissociative anaesthetic with central nervous system depressant, stimulant, analgesic, 
and hallucinogenic effects similar to phencyclidine, but less potent and of a shorter 
duration. Used in human anaesthesia and veterinary medicine. Some ketamine users 
may experience a terrifying feeling of almost complete sensory detachment that is 
likened to a near-death experience; known as the 'K-hole'
khat The leaves of the plant, Catha edulis, which are chewed or brewed as a drink
legal highs A term used to describe unregulated psychoactive substances. The term encompasses a 
wide range of synthetic and plant-derived substances and products, including ‘research 
chemicals’, ‘party pills’ and ‘herbal highs’, which are usually sold via the Internet or in 
head shops
licit drug A drug that is legally available with or without a medical prescription
liver cirrhosis Scarring of the liver and poor liver function
lysergic acid diethylamide (LSD) A semi-synthetic product of lysergic acid, a natural substance from the parasitic rye 
fungus Claviceps purpurea. See serotonergic hallucinogens
MDMA 3,4-methylenedioxymethamphetamine, a synthetic derivative of amphetamine, 
exhibiting both stimulant and mild hallucinogenic properties. Entactogenic effects 
include feelings of euphoria and solidarity, heightened sensory awareness and ease of 
contact with others. Commonly known as ecstasy, a wide range of substances, including 
MDMA analogues or 4-MTA, may appear in varying concentrations in ecstasy tablets. 
Most ecstasy tablets now available in the UK no longer contain MDMA
mescaline A hallucinogenic substance found in the peyote cactus in South-Western USA and North 
Mexico. See serotonergic hallucinogens
methadone A synthetic opioid drug
methamphetamine A derivative of amphetamine. The pure crystalline hydrochloride form of 
methamphetamine known as ‘ice’ may be smoked, achieving as rapid or even more 
rapid onset of effects than injection of methamphetamine powder (the hydrochloride 
salt form). Methamphetamine freebase is a colourless volatile oil insoluble in water
methylphenidate A mild central nervous system stimulant. Commonly used in the treatment of attention-
deficit disorders in children
modafinil A wake-promoting medication used in the treatment of narcolepsy and other sleep 
disorders. Misused with the expectation that it will improve cognitive performance
N,N-dimethyltryptamine (DMT) A plant hallucinogen. See serotonergic hallucinogens
nicotine An alkaloid and the major psychoactive substance in tobacco. Nicotine has both 
stimulant and relaxing properties
nitrazepam See benzodiazepines
nitrites Volatile inhalants
non-benzodiazepine hypnotics A class of drugs, which although chemically unrelated to the benzodiazepines, exert 
similar actions
novel synthetic drugs New drugs and drug classes that have emerged since 2003. These drugs may or may not 
be scheduled as controlled substances and in some cases may be sold as legal highs
opioid The generic term applied to alkaloids from the opium poppy (Papaver somniferum), their 
synthetic analogues, and compounds synthesised within the body
overdose The use of any drug in such an amount that acute adverse physical or mental effects are 
produced
over-the-counter products Medicines that are available without prescription
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peripheral neuropathy Disorder and functional disturbance of the peripheral nerves. Symptoms include 
numbness of the extremities, ‘pins and needles’, weakness of the limbs, or wasting of 
the muscles and loss of deep tendon reflexes
phencyclidine (PCP) A psychoactive drug with central nervous system depressant, stimulant, analgesic, and 
hallucinogenic effects. Introduced into clinical medicine as a dissociative anaesthetic
piperazines Initially developed as veterinary anthelmintic agents. Piperazines have a chemical 
structure similar to amphetamine. They have been identified in tablets sold as ecstasy. 
See novel synthetic drugs
polysubstance use The use of more than one drug or type of drug by an individual, often concurrently or 
sequentially
psilocybin A naturally occurring hallucinogen found in certain species of mushroom. See 
serotonergic hallucinogens
psychoactive drug or substance A substance that when ingested affects mental processes, e.g. cognition or effect
psychosis A loss of contact with reality, usually including delusions and hallucinations
psychotic Experiencing psychosis
relapse A return to drinking or other substance use after a period of abstinence
rhabdomyolysis A condition caused by the breakdown of skeletal muscle fibres resulting in the release of 
muscle fibre content (myoglobin) into the bloodstream
route of administration The way in which a substance is introduced into the body
Salvia divinorum A hallucinogenic plant, the leaves of which can be chewed or smoked to release a 
psychoactive compound, salvinorin A
serotonergic hallucinogens A class of hallucinogens with a method of action strongly tied to the serotonin 
neurotransmitter
serotonin syndrome A potentially life threatening drug reaction that causes the body to have too much 
serotonin
speedball Refers to the combined use of a stimulant and an opioid, most commonly simultaneous 
injection of cocaine and heroin
stimulant Any agent that activates, enhances, or increases neural activity
substituted cathinones Synthetic drugs with stimulant properties related to a plant product, cathinone. See 
novel synthetic drugs
sympathomimetic Producing physiological effects resembling those caused by the action of the 
sympathetic nervous system
synthetic cannabinoids Products typically containing synthetic cannabinoid receptor agonists sprayed onto a 
mixture of 'smokeable herbs'. The class of products is commonly known as ‘Spice’. See 
novel synthetic drugs
temazepam See benzodiazepines
THC Δ9-tetrahydrocannabinol, the most active constituent in cannabis
tolerance A decrease in response to a drug dose that occurs with continued use
tryptamine derivatives Synthetic drugs with hallucinogenic properties. Chemically related to the hallucinogen 
DMT. See novel synthetic drugs
volatile substances Substances that vaporise at ambient temperatures
Wernicke–Korsakoff syndrome A spectrum of disease resulting from vitamin B1 (thiamine) deficiency
withdrawal syndrome A group of symptoms of variable clustering and degree of severity which occur on 
cessation, or reduction of use of a psychoactive substances that has been taken 
repeatedly, usually for a prolonged period and/or in high doses
zaleplon See non-benzodiazepine hypnotics
zolpidem See non-benzodiazepine hypnotics
zopiclone See non-benzodiazepine hypnotics
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A summary of the health 
harms of drugs
1. Introduction
The health harms arising from licit and illicit substance use and misuse are wide-ranging and vary 
depending on the substance used and the pattern and context of their use, but it is well established 
that their use represents a major public health burden. This report summarises the health-related 
harms of emerging and established licit and illicit drugsa, providing an update to Dangerousness of 
drugs: a guide to the risks and harms associated with substance misuse1.
1.1 Influence of drug, set and setting
The health harms arising from licit and illicit substance use are diverse and need to be considered 
within the culture and context of drug use among specific populations. That is, drug-related harms 
do not only vary according to the different types of drug or drugs being used; alongside this, it is the 
way a drug is used, the way it is used in combination with other substances, and the social context in 
which it is used that contribute to risk.
Researchers often consider the influence of the drug (referring to the pharmacological properties 
of a drug), set (the characteristics of the person using the drug) and setting (the social and physical 
environment in which the drug is used) on drug-related harms. For example, studies have identified 
specific characteristics associated with alcohol-related harm in drinking environments, including 
crowding, low levels of comfort, cheap drink promotions, and poorly trained staff2. These factors 
may also interact, as in the case of MDMA, the acute effects of which are intensified by taking it in 
stimulating conditions such as nightclubs3. In particular, the harms associated with illicit substance 
use, or use of other unregulated psychoactive substances, are further confounded by lack of suitable 
quality control in their manufacture and distribution. People who use these substances can therefore 
only make inadequate assessments of the quality, purity, and chemical composition of any drugs 
they use4. The route or mode of administration of a drug plays a particular role in escalating risk. 
Injection drug use poses the greatest risk to users, putting them at a very high risk of acquiring blood 
borne viral infections, and at an increased risk of overdose and dependence. Injecting drug users also 
frequently face discrimination and stigmatisation, which may discourage users away from accessing 
treatment and other health services5. 
1.2 Assessing health-related harms
There are major challenges to the assessment of health-related harms of drugs. There may be 
difficulties in interpreting evidence of harm due to uncertainties whether the substance used is a 
direct or indirect cause of the acute and chronic adverse effects that have been attributed to its use. 
In addition, it may be difficult to quantify the magnitude of the risk of experiencing these health 
harms among users.
The methods used to develop the updated tables were based on the systematic retrieval and 
collection of relevant peer reviewed literature. For further details on the methodology please see the 
aThe list of licit and illicit drugs to be included in the updated tables was agreed between the research team, NTA and DH. 
For further details see the Technical Document that accompanies this report
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Technical Report that accompanies this report. Evidence from systematic reviews and well designed 
observational studies was prioritised for inclusion, providing, where available, the strongest evidence 
available of an association between the substance use in question and a particular health outcome. 
However, it was beyond the scope of the work to provide an estimation of the magnitude of the 
health risks associated with each of the substances presented. Research is ongoing to develop 
systematic and transparent approaches for the assessment of drug-related harms6,7. 
1.3 Patterns of substance use
Patterns of licit and illicit substance use in the general population underlie the nature and prevalence 
of the health harms associated with their use. The following section considers patterns of substance 
use reported by adults and young people in England and Wales.
Patterns of substance use among adults
The use and misuse of licit and illicit substances is common among the British population. The 
majority of adults consume alcohol: 69% and 55% of men and women in England and Wales, 
respectively, are weekly drinkers8; 26% of British men and 18% of British women exceed the 
recommended limits for weekly alcohol drinking; and 7% of men and 4% of women may be 
classified as higher risk drinkersb. Smoking prevalence has fallen considerably over the past three 
decades: 22% of men and 20% of women in England and Wales over the age of 16 currently 
Among 32.3 million adults aged 16 to 59 in England and Wales there are an estimated:
• 20 million weekly alcohol drinkers
• 6.8 million current smokers
• 1.6 million regular users of illicit drugs
Figure 1. Percentage of adults reporting substance use, 2009
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smoke. In addition, the proportion of heavy adult smokers (an average of 20 or more cigarettes 
a day) has also fallen over this period; currently 7% and 5% of men and women in England and 
Wales, respectively, are heavy smokers.
An estimated 36% of the adult population in England and Wales have ever used an illicit drug and 
5% have used illicit drugs in the last month. Class A drug use is less common: 15% have ever used 
a Class A drug, with 1% having used a Class A drug in the last month9. After cigarettes and alcohol, 
cannabis is by far the most commonly used substance among the general population; 4% of 16 to 
59-year olds have used the drug in the last month.
Patterns of substance use among young people
Young adults aged 16 to 24 years are more likely to use illicit drugs than older age groups; 41% 
have ever used an illicit drug and 20% have used illicit drugs in the last year. Among younger age 
groups, 22% of 11 to 15-year olds have ever used an illicit drug and 15% have used an illicit drug in 
the past year. After cigarettes and alcohol, cannabis is the most commonly used substance by young 
people; 9% of 16 to 24-year olds and 5% of 11 to 15-year olds have used cannabis in the last 
month. Among 16 to 24-year olds, 5% reported using ‘skunk’.
Among 6.6 million young people aged 16 to 24 in England and Wales there are an estimated:
• 3.5 million weekly alcohol drinkers
• 1.7 million current smokers
• 0.8 million regular users of illicit drugs
0%
10%
20%
30%
40%
50%
60%
70%
80%
16-24 yrs11-15 yrs
Any 
Class A drug
Any 
stimulant drug
CannabisAny 
illict drug
SmokingAlcohol
Figure 2. Percentage of young people reporting substance use, 2009
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amphetamines, amyl nitrate and methamphetamine. Any Class A drug: reported use in the past month, includes powder cocaine, crack cocaine, ecstasy, LSD, magic 
mushrooms, heroin, methadone and methampethamine
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The British Crime Survey 2009-10 examined use of khat and recently classified drugs finding that in 
the last year among 16 to 24-year olds, 1% had used Spice or a synthetic cannabinoid, 1% had used 
BZP, 0.5% had used GBL/GHB and 0.5% had used khat.
1.4 Dependence
There are also problems of dependence among the general population. Dependence is currently 
defined by the World Health Organisation International Classification of Diseases (ICD-10) as a 
cluster of behavioural, cognitive, and physiological phenomena which typically includes a strong 
desire to take the substance, difficulties in controlling its use despite harmful consequences, a 
higher priority given to drug use than other activities, increased tolerance, and sometimes a physical 
withdrawal state. The general principles of dependence do not apply equally to all psychoactive 
substances10 and the characteristics and severity of symptoms and signs of the dependence 
syndrome vary by drug. In addition, harmful use may occur without a substance causing physical 
or psychological dependence. Ghodse notes that “dependence is not just a manifestation of a 
specific drug effect, but is a behaviour profoundly influenced by the individual personality and the 
environment, as well as by the specific drugs that are available”11. The main concepts associated with 
drug dependence are described below.
Drug dependence
Psychological dependence
A core component of the definition of drug dependence. Described by Ghodse (2010) as “an 
overriding compulsion to take the drug even in the certain knowledge that it is harmful, and 
whatever the consequences of the method of obtaining it” (page 7).
Physical dependence
Not all drugs cause physical dependence, but for those that do, sudden drug withdrawal is followed 
by a withdrawal syndrome, characteristic of the psychoactive substance taken. Whether an individual 
develops physical dependence varies from person to person and depends on regular administration 
of the drug (e.g. daily), in sufficient dosage over a period of time (e.g. a number of years).
Withdrawal syndrome
A specific array of symptoms and signs that follow sudden withdrawal of a drug that causes physical 
dependence.
Tolerance
Following repeated administration of some drugs, users may become less sensitive to the effects of 
the drug and over time require larger doses to achieve the same effects previously produced at lower 
doses. Therefore, they may be able to tolerate much higher doses than individuals who have not 
previously been exposed to the drug. Tolerance does not necessarily develop equally or at the same 
rate for all the effects of a drug.
15
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Among the general population, alcohol dependence affects 9% of men and 3% of women in England 
and 24% of adults drink alcohol in a way that puts them at risk of physical and psychological harm12. 
There is a continuing debate about how best to characterise nicotine dependence among tobacco 
smokers13. One indicator of dependence is how soon after waking smokers smoke their first cigarette. 
Among the general population, 15% of smokers have their first cigarette within the first five minutes of 
waking14.
General population surveys estimate that around 3% of adults in England show signs of dependence 
on illicit drugs, most frequently cannabis (4% of men and 2% of women)12. For other illicit drugs, 0.4% 
show signs of dependence on cocaine and 0.1% each show signs of dependence on crack, ecstasy 
and heroin/methadone. However, general population surveys significantly underestimate the numbers 
of dependent drug users; based on estimates of opiate and crack cocaine use, there are over 320,000 
opiate and/or crack cocaine users in England (equivalent to approximately 0.9% of the population).
1.5 Substance-related deaths
Alcohol
Alcohol use has been linked to the development of a number of chronic conditions and acute 
consequences, ranging from cancer to road traffic accidents. There were 7,075 alcohol-related 
deaths in England and Wales in 2009, if only the causes of death regarded as being most directly 
due to alcohol consumption are includedc. There were more alcohol-related deaths among men than 
women; 4,649 deaths among men and 2,426 deaths among women. 
Using a broader definition of alcohol-related deaths, the North West Public Health Observatory 
estimated that in 2005 there were 14,982 deaths attributable to alcohol consumption15, representing 
3% of all deaths in England for that year. Alcohol-related deaths varied by age, and young people 
were disproportionally affected by their alcohol use. For example, among males it was estimated that 
27% of deaths among 16-24 year olds were attributable to alcohol consumption.
Smoking
Smoking-related deaths have been attributed to a range of diseases including cardiovascular disease, 
respiratory disease (including chronic obstructive pulmonary disorder) and lung cancer. Nineteen 
per cent of all deaths in the UK were estimated to be directly attributable to smoking in 200516. In 
2009, an estimated 81,400 deaths among adults aged 35 and over were attributable to smoking, 
representing 18% of all deaths for that year17.
Illicit drugs
The majority of recorded drug-related deaths are related to opioid use and mostly occur among 
injecting drug users18. In 200919, there were 2,878 deaths in England and Wales related to drug 
poisoning and 1,876 drug misuse deathsd. Of deaths from drug-related poisoning, 880 involved 
Among 33.7 million adults aged 16 to 64 in England there are:
• 2.4 million adults who show signs of dependence on alcohol
• 1.4 million adults who show signs of dependence on illicit drugs
cBased on the current Office for National Statistics definition of alcohol-related deaths
dDefined as deaths where the underlying cause is drug abuse or drug dependence or deaths where the underlying 
cause is drug poisoning and where any of the substances controlled under the Misuse of Drugs Act (1971) are involved
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heroin or morphine, 378 deaths involved methadone, 261 involved benzodiazepines and 202 
involved cocaine. An alternative source of data on drug-related deaths is published by the National 
Programme on Substance Abuse Deaths (np-SAD). In 2009, there were 1,524 drug-related deaths 
in England reported to the programme20. The main cause of death was accidental poisoning and 
heroin/morphine were the principle substances implicated in deaths. 
However, neither of these sources take into account other deaths related to illicit drug use such as 
those from blood borne infections, violent assaults, and suicides. For example, deaths from AIDS 
among injecting drug users accounted for 8% of all AIDS deaths in England and Wales in 200921.
1.6 The economic costs of substance use
Health care
Studies of the health-related costs of substance use indicate an annual spend of nearly £3bn on 
alcohol misuse in England22, in the region of £5 billion on smoking-related ill health in the UK16, and 
just under £500m on Class A drug use in England and Wales23. Hospital admissions arising from 
diseases or conditions directly and indirectly related to substance use make a large contribution to the 
costs to the NHS. The most recent data available indicates that each year there are over one million 
admissions related to alcohol consumption24, and over 45,000 admissions attributable to smoking 
among people over 3517. In relation to illicit drug use, there are around 5,800 admissions for drug-
related mental health and behavioural disorderse each year and over 11,500 admissions for drug 
poisoning25. These statistics, however, do not take into account other types of drug-related hospital 
admissions, for example, those related to respiratory disease, HIV-related illness, chronic liver disease 
associated with hepatitis C infection and injection site infections. In addition, older people who 
continue to use drugs and require the support of health services are emerging as an important but 
relatively under-researched population.26
Substance-related crime
Although it is difficult to estimate the number of offences that are related to alcohol or illicit drug 
use, it is well established that there is a link between substance use and acquisitive crime. The 2005 
Offending Crime and Justice Survey27 included questions on offending among young people aged 
10 to 25 years related to alcohol and illicit drug use. For 18% of all violent offences and 10% of all 
property offences, offenders were under the influence of alcohol only. For 3% and 2% of all violent 
offences and all property offences, respectively, offenders were under the influence of illicit drugs 
only.
In 2008, the Home Office calculated that the costs associated with alcohol-related crime were 
between £8.75bn and £14.78bn28. These costs were mainly incurred as a result of less serious 
wounding, criminal damage, sexual offences and causing death by dangerous driving. The costs 
associated with drug-related crime were last updated in 2003-04 and estimated at £13.32bn23. The 
estimation of these costs included the following offence categories: fraud, burglary, robbery and 
shoplifting. 
eIncluding admissions for acute intoxication, harmful use, dependence syndrome, withdrawal state, psychotic disorder, 
amnesic syndrome and other disorders
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1.7 The updated tables
The basic layout of the updated tables follows the ‘framework for typology of dangerousness of 
drugs’ as outlined in the 2003 report, focusing on the acute and chronic adverse effects associated 
with each substance and factors that mediate or moderate the risk. 
Following the format of the 2003 report, evidence on specific harms associated with different 
contextual factors related to drug use (different routes of administration, polypharmacy, and age and 
gender-related factors) have been included in the updated tables for each specific drug, and as a set 
of new tables addressing these as cross-cutting themes across the included substances. Two additional 
tables also consider the potential health risks arising from adulterants. 
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PART TWO 
THE UPDATED TABLES
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1. Alcohol
PHYSICAL
PSYCHOLOGICAL/PSYCHIATRIC
MORTALITY MORBIDITY
Large doses (blood alcohol concentrations 
greater than 3-4 g/L) may lead to:
 • coma and death
 • asphyxiation
 • respiratory depression
Heavy drinking episodes associated with:
 • acute pancreatitis
 • cardiovascular deaths
Increased mortality associated with accidents 
including:
 • road traffic accidents
 • drowning
 • deaths from fire
 • workplace accidents
 • falls
Violence and injuries
 • increased morbidity associated with violence  
 (e.g. assaults) and accidents
Physiological responses
 • low blood sugar (hypoglycaemia)
 • raised blood pressure, irregular heartbeat  
 (arrhythmia)
 • sleep disturbance
 • decrease in sharpness of vision, hearing, and  
 other senses
 • decreased coordination and loss of balance  
 (ataxia)
 • drowsiness, loss of consciousness
 • facial flushing
 • hypothermia
 • increased rate of urination (diuresis),   
 dehydration
Gastrointestinal complications
 • gastritis, vomiting and acid reflux from acute  
 intake of large amounts of alcohol
 • diarrhoea, nausea
 • rupture of the oesophageal mucosa;   
 associated with vomiting after drinking   
 (Mallory-Weiss tears) 
Organic/neurological
 • impairment in memory, planning and   
 judgement (psychomotor and   
 cognitive impairment)
 • temporary loss of the ability to form new  
 memories (anterograde amnesia)
 • memory blackout
Personality/mood
 • reduced inhibitions
 • argumentative and aggressive behaviour
 • thoughts about suicide (suicidal ideation) may  
 be intensified with alcohol use
1.1 Acute adverse effects associated with the use of alcohol
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PHYSICAL
PSYCHOLOGICAL/PSYCHIATRIC DEPENDENCE/ WITHDRAWAL/ TOLERANCE
MORTALITY MORBIDITY
Violence and injuries
 • increased risk of premature   
 mortality from accidents, suicide  
 and violence
Liver disease
 • alcoholic hepatitis
 • liver cirrhosis
Cardiovascular complications
 • disease of the heart muscles   
 (cardiomyopathy)
 • coronary heart disease
 • abnormal heart rhythm   
 (arrhythmia)
Neurological complications
 • haemorrhagic stroke
Cancers
 • mouth and throat (lip, oral cavity,  
 pharynx and larynx)
 • digestive system (oesophagus,  
 colon and rectum)
 • liver
 • breast
Gastrointestinal complications
 • gastrointestinal bleeding
 • pancreatitis
 • gastritis
 • peptic ulcer disease, evidence is  
 inconclusive but higher   
 prevalence in patients with liver  
 cirrhosis
 • enlarged and damaged veins in  
 the lower oesophagus
Neurological complications
 • risk factor for first epileptic   
 seizure
Infectious diseases
 • risk factor for incidence and   
 re-infection of tuberculosis
Muscle, joint and bone
 • damage to the peripheral   
 nervous  system (peripheral   
 neuropathy/polyneuropathy)
 • muscle weakness and pain   
 (myopathy)
Cardiovascular complications
 • high blood pressure   
 (hypertension)
 • alcohol-related heart failure   
 (alcoholic cardiomyopathy)
Gastrointestinal complications
 • pancreatitis
 • gastritis
 • peptic ulcer disease, evidence is  
 inconclusive but higher   
 prevalence in patients with liver  
 cirrhosis
 • enlarged and damaged veins in  
 the lower oesophagus
Liver disease
 • fatty liver disease
 • alcoholic hepatitis
 • cirrhosis of the liver
Reproductive disorders
 • disrupts the menstrual cycle and  
 ovulation
 • can reduce chances of conception
 • long-term alcohol abuse has   
 been linked to sexual dysfunction  
 and impairment of sperm   
 production in men
Complications in pregnancy
 • spontaneous abortion
 • still birth
 • preterm delivery and decrease in  
 length of gestation
 • decreased foetal growth and   
 birth weight
 • fetal alcohol syndrome – a   
 clearly-defined disorder   
 particularly seen in heavy drinkers
 • fetal alcohol spectrum disorder –  
 a more recent categorisation that  
 acknowledges the likely wider  
 impacts of varying levels of   
 alcohol consumption on the   
 developing foetus
Organic/neurological
 • neurobiological brain injury
 • alcoholic cerebellar degeneration
 • deficiency of vitamin B1   
 (Wernicke–Korsakoff syndrome) 
 • memory loss, memory blackouts
Personality/mood
 • psychotic symptoms during   
 intoxication or withdrawal   
 (including depression, paranoia  
 and anxiety)
 • loss of self esteem
Dependence
 • a range of dependence issues,  
 from mild through to   
 moderate to severe:
moderate dependence –   
characterised by raised level of  
tolerance, symptoms of alcohol  
withdrawal and impaired control 
over drinking;
severe dependence –   
characterised by severe alcohol  
withdrawal and high tolerance;  
individuals may have 
experienced withdrawal fits or 
delirium tremens, and they may 
drink to avoid symptoms of 
withdrawal
Withdrawal
 • withdrawal can be fatal
 • convulsions
 • tremors
 • anxiety
 • paranoia
 • hallucinations
 • sudden and severe mental or   
 neurological changes (delirium  
 tremens)
Tolerance
 • tolerance to the toxic effects may  
 not develop in parallel with   
 tolerance to the central nervous  
 system depressant effects   
 – increases the likelihood of drug  
 induced organ damage
 • increased capacity to metabolise  
 alcohol (declines after several   
 weeks of abstinence)
1.2 Chronic adverse effects associated with the use of alcohol
1. Alcohol
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ROUTE OF 
ADMINISTRATION/
DOSE
COMBINATION USE 
(CONCURRENT USE, 
CONSECUTIVE USE)
AVAILABILITY/ 
PURITY
SOCIAL CONTEXT/ 
SETTING
AGE /
DEVELOPMENTAL 
ISSUES*
INDIVIDUAL 
VULNERABILITY LEGAL SITUATION
Route of 
administration
 • rare reports of  
 intravenous use  
 among   
 polysubstance  
 users
Dose
 • risk of coma and  
 death associated  
 with bouts of  
 heavy drinking
Concurrent use
 • link between  
 cigarettesmoking  
 and alcohol use
 • commonly used  
 in combination  
 with sedatives,  
 opioid drugs,  
 cannabis and  
 amphetamines
 • alcohol used in  
 combination with  
 opioid drugs is a  
 significant risk  
 factor for  
 overdose by  
 respiratory  
 depression
 • a metabolite  
 (cocaethylene) is  
 formed following  
 concurrent use of  
 alcohol and  
 cocaine – toxic  
 effects of this  
 combination are  
 commonly seen  
 in cocaine related  
 deaths
Availability
 • age limit of 18  
 on purchase
 • readily available  
 from on and  
 off-licensed  
 premises
 • alcohol has  
 become more  
 affordable over  
 the last two  
 decades
Social context
 • alcohol use is  
 perceived  
 differently by  
 different societies  
 (‘wet’ versus  
 ‘dry’ cultures or  
 subcultures)
Developmental 
issues
 • alcohol use in  
 early adolescence  
 is a risk factor for  
 later drug use
 • heavy drinking  
 during   
 adolescence is  
 associated with  
 cognitive deficits,  
 with implications  
 for learning and  
 other cognitive  
 abilities, that may  
 worsen as  
 drinking  
 continues into  
 late adolescence  
 and young  
 adulthood
 • early age of  
 drinking onset is  
 associated with  
 an increased  
 likelihood of  
 developing  
 alcohol abuse or  
 dependence in  
 adolescence and  
 adulthood 
 • heavy drinking in  
 adolescence may  
 have an adverse  
 effect on  
 reproductive  
 development;  
 suggestion that  
 continued use  
 into adulthood  
 may affect  
 reproductive  
 functions
 • inherited  
 deficiency of a  
 particular  
 enzyme  (ALDH2)  
 causes the  
 relatively high  
 frequency of  
 flushing in East  
 Asian populations  
 (a protective  
 factor against  
 alcohol use  
 disorders)
 • genetic factors  
 may influence  
 the risk of  
 individuals  
 experiencing  
 problems with  
 alcohol use
 • people who are  
 diabetic may  
 become  
 hypoglycaemic as  
 a result of  
 alcohol use
Not controlled 
under the Misuse  
of Drugs Act 1971
1.3 Factors that mediate and moderate harms associated with the use of alcohol 
1. Alcohol
*For further duscussion on the effects of alcohol use from a developmental perspective, see Brown et al (2008).
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2. Amphetamines*
2.1 Acute adverse effects associated with the use of amphetamines
PHYSICAL
PSYCHOLOGICAL/PSYCHIATRIC
MORTALITY MORBIDITY
Excitation syndrome
 • abnormal heart rhythms (arrhythmias)   
 associated with collapse/cardiac arrest leading  
 to sudden death
Vascular accidents
 • increase in blood pressure (hypertension)
 • stroke
 • heart attack (myocardial infarction)
 • cardiovascular shock
Acute intoxication
 • agitation/aggression
 • pupil dilation
 • headache
 • tremors and writhing movements of the body  
 and limbs (dyskinesia)
 • nausea, abdominal cramps
 • dry mouth
 • sweating
 • anorectic effects, decreased appetite
 • increase in body temperature (hyperthermia)
 • increased breathing rate, blood pressure and  
 heart rate (possible arrhythmia)
 • dizziness, tremor, irritability and confusion 
 • hallucinations
 • convulsions
Methamphetamine
Acute intoxication
 • more pronounced central nervous system  
 stimulant effects and longer duration of effect  
 than amphetamine sulphate
Lifestyle factors
 • use strongly associated with risky sexual   
 practices
Organic/neurological
 • toxic delirium with amnesia 
 • as stimulant effects dissipate users may   
 experience drowsiness, reduced ability to  
 concentrate, and/or judgement and learning  
 impaired
Personality/mood
 • low mood (dysphoria)
 • anxiety, depression
 • irritability, aggression
Acute paranoid psychosis
 • psychotic reaction similar to acute paranoid  
 schizophrenia (vivid visual, auditory, or tactile  
 hallucinations, paranoid ideation possibly  
 resulting in aggressive behaviour)
 • may develop after single or repeated   
 ingestion of amphetamines
 • people with underlying mental health   
 problems are at greatest risk
*Including amphetamine sulphate and methamphetamine. 
For MDMA and related analogues, see table 3
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PHYSICAL
PSYCHOLOGICAL/PSYCHIATRIC DEPENDENCE/ WITHDRAWAL/ TOLERANCE
MORTALITY MORBIDITY
Excitation syndrome
 • abnormal heart rhythms   
 (arrhythmias) associated with  
 collapse/cardiac arrest leading to  
 sudden death 
Cardiovascular complications
 • inflammation of the blood vessels  
 (vasculitis)
 • aortic dissection 
 • cardiovascular shock
Other complications
 • depression leading to suicide
Cardiovascular complications
 • cumulative risk of cardiac and  
 coronary artery disease
 • abnormally high blood pressure  
 in the arteries of the lungs   
 (pulmonary hypertension)
 • inflammation of the blood vessels  
 (vasculitis)
 • bleeding into and along the wall  
 of the aorta, the major artery   
 carrying blood from the heart  
 (aortic dissection)
Lifestyle factors
 • negative health effects from lack  
 of food and sleep, such as lower  
 resistance to disease
Complications in pregnancy
 • use in pregnancy has been   
 associated with low birth weight,  
 prematurity and increased foetal  
 morbidity
 • confounded by the impact of   
 other situational, health and   
 lifestyle factors, and   
 polysubstance use
Organic/neurological
 • cognitive deficits associated with  
 damage to the nervous system  
 and brain (e.g. impairment of  
 memory, learning and monitoring  
 of complex goal-directed   
 behaviour [executive function])
 • behaviour stereotypes –   
 mechanical hyperactivities,   
 repetitive actions, stereotype   
 motor phenomena (e.g. teeth  
 grinding)
Chronic paranoid psychosis
 • psychotic reaction similar to   
 paranoid schizophrenia –   
 hallucinations, paranoid ideation  
 possibly resulting in aggressive  
 behaviour, potentially reversible
 • incidence and severity of   
 methamphetamine psychosis   
 related to frequency of use and  
 injection or smoking as the route  
 of administration 
 • symptoms usually resolve with  
 abstinence, but case reports   
 suggest some methamphetamine  
 users may experience prolonged  
 or recurrent psychosis, even after  
 stopping use
Personality/mood
 • irritability
 • suspiciousness
 • dysphoria
 • anxiety
 • paranoid psychosis
 • depression
 • restlessness
 • delirium
 • depersonalisation
 • feelings of persecution
 • lethargy
Methamphetamine
Personality/mood
 • user reports of physical   
 aggression
Dependence
 • high abuse potential due to   
 mood elevating properties
 • good evidence for an   
 amphetamine dependence   
 syndrome
 • typically occurs after a period of  
 sustained regular use
Withdrawal
 • rarely life threatening
 • symptoms may include   
 depression (increasing risk of   
 suicide), seclusiveness, craving,  
 fatigue/exhaustion, weakness,  
 lack of energy and sleep   
 disturbance
 • psychotic symptoms may also be  
 a feature of the    
 methamphetamine withdrawal  
 syndrome
Tolerance
 • users may become tolerant to the  
 euphorigenic, anorectic,   
 hyperthermic and cardiovascular  
 effects
2.2 Chronic adverse effects associated with the use of amphetamines
2. Amphetamines
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ROUTE OF 
ADMINISTRATION/
DOSE
COMBINATION USE 
(CONCURRENT USE, 
CONSECUTIVE USE)
AVAILABILITY/ 
PURITY
SOCIAL CONTEXT/ 
SETTING
AGE /
DEVELOPMENTAL 
ISSUES
INDIVIDUAL 
VULNERABILITY LEGAL SITUATION
Route of 
administration
 • use by injection
 • smoking
 • crystalline  
 hydrochloride  
 form of   
 methampheta- 
 mine (‘ice’) is  
 potentially more  
 harmful than  
 other forms due  
 to relatively high  
 purity and ease  
 with which it can  
 be smoked
Concurrent use
 • in combination  
 with alcohol  
 – increase in  
 perceived total  
 intoxication 
 • in combination  
 with cocaine  
 – limited  
 evidence but  
 may have  
 harmful   
 cardiovascular  
 effects (e.g. one  
 case of   
 vasospasm  
 reported in the  
 literature)
Availability
 • amphetamine  
 use has declined  
 since the  
 mid-1990s
 • no evidence of  
 increasing use of  
 methampheta- 
 mine in the UK,  
 use remains low
Purity
 • amphetamine  
 purity low in UK  
 at a mean of 8%  
 (2009 data)
 • generally low  
 methampheta- 
 mine purity in  
 the UK at a mean  
 of 9% (2001–04  
 data)
Social context/
setting
 • amphetamine  
 use combined  
 with hot,  
 crowded settings  
 may result in  
 overheating and/ 
 or exhaustion
Age
 • most   
 amphetamine  
 users are young  
 adults who  
 primarily use the  
 drug for a  
 relatively short  
 period of time 
 • chronic paranoid
 • psychosis
 • genetic   
 predisposition to  
 psychotic  
 reaction
Misuse of Drugs 
Act 1971
Class A
amphetamines 
prepared for 
injection, 
methamphetamine
Class B
oral amphetamines 
2.3 Factors that mediate and moderate harms associated with the use of amphetamines 
2. Amphetamines
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3. MDMA and related substances*
3.1 Acute adverse effects associated with the use of MDMA and related substances
PHYSICAL
PSYCHOLOGICAL/PSYCHIATRIC
MORTALITY MORBIDITY
Overheating/heat stroke (hyperthermia)
 • major acute symptom of MDMA-related  
 toxicity that can lead to death
 • associated with serotonin syndrome, and  
 complications including rhabdomyolysis,  
 abnormal blood clotting (disseminated   
 intravascular coagulation), kidney failure and  
 liver failure
Swelling of the brain (cerebral oedema)
 • caused by low sodium levels (hyponatraemia)  
 secondary to water intoxication
 • propensity for women to be    
 disproportionately affected
Other complications
 • fatal cases of liver damage are rare
 • small number of case reports have linked the  
 use of ecstasy with cerebrovascular accidents  
 (e.g. stroke)
 • a few fatalities have been reported in the  
 literature associated with the use of   
 ‘counterfeit ecstasy’ containing   
 paramethoxymethamphetamine (PMMA)  
 and/or paramethoxyamphetamine (PMA)
 • many MDMA-related fatalities are   
 attributable to polysubstance use (multiple  
 drug toxicity)
Acute intoxication
 • elevated blood pressure and increased heart  
 rate (palpitations)
 • nausea, vomiting
 • fatigue, dizziness and/or vertigo 
 • overheating, dehydration
 • headache
 • dry mouth and throat
 • loss of appetite
 • difficulty with bodily coordination, muscle  
 aches or tightness
 • agitation/aggression
 • convulsions
Other complications
 • may inhibit orgasm in men and women, and  
 male erection
 • examples of acute liver injury reported in the  
 literature – may be secondary to hyperthermia  
 or caused by direct drug toxicity
 • associated with risk taking in general, and  
 sexual risk taking in particular
 • teeth grinding and clenching (bruxism)/teeth  
 problems 
Personality/mood
 • anxiety, panic attacks
 • confusion
 • depressive symptomatology
 • insomnia
 • restlessness
 • fatigue
 • anorexia
 • paranoia
 • visual and auditory hallucinations are rare –  
 tend to be associated with high doses
 • suggestions that may have mild and transient  
 effects on cognition after acute administration
 • individual or unpredictable psychotic episodes  
 may occur
 • incorrect interpretation of emotions and other  
 social cues
4-Methylthioamphetamine (4-MTA) 
Personality/mood
 • has a greater propensity to cause visual   
 hallucinations than MDMA
*3,4-Methylenedioxymethamphetamine (MDMA) and related analogues, including 3,4-methylenedioxyamphetamine (MDA), 3,4-methylenedioxyethylamphetamine 
(MDEA), methylbenzodioxolylbutanamine (MBDB), 3-methoxy-4,5-methylenedioxyamphetamine (MMDA), 4-methylthioamphetamine (4-MTA)
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PHYSICAL
PSYCHOLOGICAL/PSYCHIATRIC DEPENDENCE/ WITHDRAWAL/ TOLERANCE
MORTALITY MORBIDITY
 • not documented, limited   
 evidence base
Immune function
 • emerging evidence that MDMA  
 may have immunosuppressive  
 properties – users report   
 increased susceptibility to minor  
 ailments including colds, flu, sore  
 throats
Other complications
 • possible liver damage
Organic/neurological
 • unclear whether long term use is  
 associated with memory and   
 learning (cognitive) impairment
 • growing evidence that chronic,  
 heavy use is most strongly   
 associated with subtle cognitive  
 effects
 • unclear whether deficits reflect  
 the use of MDMA or the   
 combination of MDMA and   
 other substances
Personality/mood
 • repeated use may have long-  
 lasting effects on mood and   
 personality characteristics such as  
 depression and anxiety, but   
 evidence is inconsistent
Animal studies
 • an excess of serotonin in the   
 central nervous system   
 (serotonergic toxicity) has been  
 demonstrated in experimental  
 animal studies of MDMA
 • inconsistent effects in humans –  
 may result in increased risk of  
 depression or other mental illness  
 later in life but the equivalence is  
 uncertain
Dependence
 • evidence for a dependence   
 syndrome is limited
 • in cases of dependence, the   
 psychological aspects of   
 dependence appear to   
 predominate
Withdrawal
 • features of a withdrawal   
 syndrome are not clearly defined  
 and mainly based on user reports
Tolerance
 • tolerance potential, but evidence  
 is based on self-report
3.2 Chronic adverse effects associated with the use of MDMA and related substances
3. MDMA and related substances
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ROUTE OF 
ADMINISTRATION/
DOSE
COMBINATION USE 
(CONCURRENT USE, 
CONSECUTIVE USE)
AVAILABILITY/ 
PURITY
SOCIAL CONTEXT/ 
SETTING
AGE /
DEVELOPMENTAL 
ISSUES
INDIVIDUAL 
VULNERABILITY LEGAL SITUATION
Route of 
administration
 • use by injection  
 (rare)
 • MDMA powder  
 may be snorted  
 (insufflated)  
 influence of set  
 and setting has  
 greater impact at  
 a lower dose  
 compared with  
 hallucinogens
Dose
 • as dose increases, 
 pharmacological  
 properties of the  
 drug override the  
 effect of set and  
 setting
 • ‘ecstasy’ tablets  
 may contain a  
 combination of  
 MDMA and  
 related   
 substances  
 – others may not  
 actually contain  
 any MDMA
Concurrent use
 • in combination  
 with cocaine  
 – evidence from  
 animal studies  
 suggests an  
 increased risk of  
 neurotoxicity
 • in combination  
 with alcohol  
 – reduce  
 perceived levels  
 of intoxication  
 but not   
 associated  
 impairments
 • in combination  
 with cannabis  
 – may potentially  
 experience  
 cumulative CNS  
 impairment and  
 may increase  
 susceptibility to  
 colds and flu
Consecutive use
 • reports of using  
 benzodiazepines  
 or heroin to self  
 medicate adverse  
 effects (especially  
 during the ‘crash  
 period’)
Availability
 • poor availability  
 of MDMA in the  
 UK; most  
 ‘ecstasy’ tablets  
 don’t contain  
 MDMA
 • market  is  
 generally well  
 informed and  
 may shift  
 patterns of use  
 depending on:  
 rumours or  
 evidence  
 regarding pill  
 content; media  
 campaigns  
 (including reports  
 on inconsisten- 
 cies in research  
 findings and  
 potential uses of  
 MDMA in  
 psychotherapy);  
 or availability of  
 drugs likely to act  
 as MDMA/ 
 ecstasy substi- 
 tutes (e.g.  
 mephedrone)
Purity
 • MDMA powder  
 has become  
 increasingly  
 popular due to  
 perceived higher  
 levels of purity,  
 but little forensic  
 evidence to  
 support this  
 conclusion
Social context/
setting
 • overcrowding  
 and overheating  
 at unregulated  
 dance events  
 may increase risk  
 of hyperthermia  
 or dehydration
Age
 • no clear evidence  
 on relationship  
 between uptake  
 of ecstasy and  
 use of other  
 drugs or drug  
 careers
 • individual  
 vulnerability for  
 acute physical  
 problems include  
 previous history  
 of epilepsy, and  
 cardiovascular or  
 cerebrovascular  
 disease
 • ‘poor   
 metaboliser’  
 status – two  
 phenotypes in  
 the population of  
 the enzyme that  
 metabolises  
 ecstasy –  
 influence of  
 metaboliser  
 status is not  
 known
 • psychological  
 vulnerability  
 increased with  
 previous or  
 current history of  
 psychiatric illness,  
 or family history
Misuse of Drugs 
Act 1971
Class A
MDMA and MDA 
family (MDMA, 
MDA, MDEA, 
MBDB, MMDA, 
4-MTA)
3.3 Factors that mediate and moderate harms associated with the use of MDMA and related substances 
3. MDMA and related substances
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4. Anabolic agents*
4.1 Acute adverse effects associated with the use of anabolic agents
PHYSICAL
PSYCHOLOGICAL/PSYCHIATRIC
MORTALITY MORBIDITY
 • few recorded cases in the UK of mortality  
 directly linked to AAS use
Injecting complications
 • users may have additional risks from injecting,  
 including damage to the injection site and  
 surrounding structures
Clenbuterol
Acute effects
 • anxiety
 • palpitations
 • shortness of breath
 • abnormal heart rhythm (atrial fibrillation)
 • increased heart rate
 • heart attack
Personality/mood
 • anti-social behaviour
 • aggression
 • hypomania
 • mania
 • paranoia
 • psychosis
 • violence
*Anabolic-androgenic steroids (AAS), growth hormone, clenbuterol and (human and non-human) chorionic gonadotropin (hCG)
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PHYSICAL
PSYCHOLOGICAL/PSYCHIATRIC DEPENDENCE/ WITHDRAWAL/ TOLERANCE
MORTALITY MORBIDITY
Vascular complications
• heart attack
• sudden cardiac death
• stroke
Liver damage
• a small number of deaths have  
 been attributed to liver injury   
 from AAS use 
Vascular complications
 • high blood pressure (hypertension)
 • altered lipid metabolism
 • heart attack (myocardial infarction)
 • stroke
 • blood clot formation (thrombosis)
 • thickening of the heart muscle  
 (cardiac hypertrophy)
Liver damage
 • acute liver injury associated with  
 particular type of anabolic steroid  
 (17α-alkylated oral steroids)
 • chronic liver damage (a few cases  
 reported of benign liver tumours,  
 blood-filled cavities in the liver  
 [peliosis hepatis] and liver cancer)
Other complications
 • acne (occasionally a severe form)
 • disruption of the normal pattern  
 of growth and behavioural   
 maturation in adolescence (e.g.  
 stunting of height, virilization)
 • tendon/ligament damage thought  
 to be due to disproportionate   
 growth of muscle
 • scalp hair loss/growth of body hair
 • disordered sleep
 • bacterial and fungal infections as  
 a result of poor injecting   
 technique or contaminated drugs
 • growth hormone users may   
 develop some of the clinical   
 features of a chronic metabolic  
 disorder, acromegaly
Males
Potentially reversible effects:
 • inhibiting effect on normal   
 testicular function – reduced   
 testosterone and sperm   
 production, shrinking of the   
 testicles (testicular atrophy)
 • prostate cancer (based on a few  
 case reports)
 • erectile dysfunction 
Potentially irreversible effects:
 • growth of the glandular breast  
 tissue (gynaecomastia)
 • scalp hair loss
Females
Effects are potentially irreversible:
 • masculinising/virilization – growth  
 of body and facial hair, deepening  
 of voice, clitoris enlargement,   
 increased libido, reduced breasts 
 • scalp hair loss
 • menstruation irregularities or   
 amenorrhoea
 • reduced fertility 
 • AAS are teratogenic – use of   
 these and other anabolic agents  
 are contraindicated in pregnancy
Personality/mood
 • anti-social behaviour
 • aggression
 • depression
 • hypomania
 • mania
 • paranoia
 • psychosis
 • suicide
 • violence
Dependence
 • some evidence to suggest   
 dependence potential
 • positive psychological effects   
 experienced may reinforce the  
 continuing use of steroids for   
 some users
Withdrawal
 • unclear, but depression has been  
 noted as common when on an  
 'off cycle' or ceasing use
 • may persist for many months and  
 similar to that seen in clinical   
 populations with decreased   
 functional activity of the sex   
 glands (hypogonadism)
4.2 Chronic adverse effects associated with the use of anabolic agents
4. Anabolic agents
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ROUTE OF 
ADMINISTRATION/
DOSE
COMBINATION USE 
(CONCURRENT USE, 
CONSECUTIVE USE)
AVAILABILITY/ 
PURITY
SOCIAL CONTEXT/ 
SETTING
AGE /
DEVELOPMENTAL 
ISSUES
INDIVIDUAL 
VULNERABILITY LEGAL SITUATION
Route of 
administration
 • majority of users  
 inject AAS and  
 use oral AAS
Dose
 • AAS users often  
 consume 10-100  
 times the  
 therapeutic dose
 • cycling is where  
 AAS are taken  
 for a period of  
 time (e.g. 6–12  
 weeks) known as  
 an 'on cycle',  
 followed by a  
 similar period of  
 steroid-free  
 training known  
 as an 'off cycle'
 • cycling is  
 practised to  
 prevent tolerance  
 to the AAS,  
 reduce the risk of  
 side effects from  
 prolonged use,  
 and allow the  
 hypothalamic- 
 pituitary-gonadal  
 axis time to  
 resume normal  
 function
 • a minority (such  
 as some  
 competitive  
 bodybuilders)  
 may use the  
 drugs on an  
 almost   
 continuous basis;  
 anecdotal reports  
 suggest that  
 some individuals  
 continue to use  
 various drugs  
 during the 'off  
 cycle'
Concurrent use
 • users will  
 typically take two  
 or more different  
 AAS at the same  
 time in a practice  
 known as  
 ‘stacking’ which,  
 based on the  
 different effects  
 AAS can exert,  
 users believe will  
 have specific,  
 additional or  
 synergistic effects
 • users may also  
 take a   
 combination of  
 ancillary drugs
Examples include:
 • tamoxifen – to  
 prevent or reduce  
 gynaecomastia
 • human chorionic  
 gonadotrophin  
 – to stimulate  
 secretion of  
 testosterone
 • diuretics – to  
 counteract fluid  
 retention caused  
 by AAS and  
 sharpen  
 definition of  
 skeletal muscle  
 contours
 • some evidence of 
 crossover to  
 stimulant use
Availability
 • majority of  
 products  
 obtained from  
 the illicit market
 • available in some  
 gyms but  
 internet sites are  
 increasingly  
 important for the  
 distribution of  
 anabolic agents  
 and related drugs 
Purity
 • concerns over  
 quality and safety  
 of drugs from the  
 illicit market  
 – suggestion that  
 falsified,  
 substandard and  
 counterfeit  
 products are  
 common  
 (including  
 microbial  
 contamination of  
 injectable drugs)
Social context/
setting
 • gyms
 • used primarily by  
 males 
 • may use due to  
 their participation  
 in sport   
 (including  
 bodybuilding);  
 for occupational  
 reasons (e.g.  
 door supervisors,  
 first responders);  
 to enhance body  
 image: to get  
 'bigger', 'look  
 better'; or to  
 prevent or treat  
 disease (such as  
 anti-ageing or  
 HIV-related  
 wasting)
Developmental 
issues
 • disruption of the  
 normal pattern of  
 growth and  
 behavioural  
 maturation in  
 adolescence (e.g.  
 stunting of height  
 and virilization in  
 case of AAS)
 • AAS are  
 teratogenic; use  
 of these and  
 other anabolic  
 agents are  
 contraindicated  
 in pregnancy 
 • tendency  
 towards  
 aggression and  
 violence in some  
 users with  
 aggressive  
 personalities
Misuse of Drugs 
Act 1971
Class C
AAS (named 
compounds and 
generic 
definition*), 
human growth 
hormone, 
recombinant 
human growth 
hormone, 
clenbuterol and 
human chorionic 
gonadotropin 
(hCG), non-human 
chorionic 
gonadotropin, 
Zeranol, Zilpaterol
4.3 Factors that mediate and moderate harms associated with the use of anabolic agents 
4. Anabolic agents
*Exempt from the prohibition on possession for personal use (including import and export) when in the form of a medicinal product
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5. Cannabis*
PHYSICAL
PSYCHOLOGICAL/PSYCHIATRIC
MORTALITY MORBIDITY
 • no cases of fatal overdose have been reported
 • no confirmed cases of human deaths
Acute intoxication
 • irritant effects of smoke on the respiratory  
 system (coughing, sore throat and   
 bronchospasm among people with asthma)
 • facial flushing
 • abdominal pain, nausea, vomiting
 • can cause an increase in heart rate   
 (tachycardia) and in some cases increased  
 blood pressure (hypertension)
 • difficulty in motor co-ordination and   
 performance
Synthetic cannabinoids
 • not documented, limited evidence base
Organic/neurological
 • perceptual distortion (hallucinations)
 • amnesia/forgetfulness
 • confusion of thought processes, impaired  
 judgement
Personality/mood
 • the effects of cannabis upon mental state vary  
 considerably between individuals; determined  
 by dose, route of administration, expectations,  
 concomitant use of other drugs, emotional  
 state, and psychiatric illness:
– temporary psychological distress   
 (especially naive users)
– low mood (dysphoria)
– anxiety
– confusion
– drowsiness
– depression
– panic attacks
– agitation
– symptoms indicative of a persistent and  
 pervasive elevated (euphoric) or irritable  
 mood (hypomanic symptoms)
– short-lived and reversible psychotic   
 reaction
Synthetic cannabinoids
Organic/neurological
 • suggestion that overdose could include   
 significant alterations in mental state with  
 paranoia and perceptual distortions
5.1 Acute adverse effects associated with the use of cannabis
*Cannabis (cannabis sativa) and synthetic cannabinoids
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PHYSICAL
PSYCHOLOGICAL/PSYCHIATRIC DEPENDENCE/ WITHDRAWAL/ TOLERANCE
MORTALITY MORBIDITY
Cancers
 • no conclusive evidence that   
 cannabis causes cancer 
 • cannabis use may be an   
 important risk factor for the   
 development of respiratory   
 cancers but the relationship is  
 unclear*
Chronic respiratory disease*
 • chronic bronchitis
 • lung damage
 • number of reports in the   
 literature of an association   
 between cannabis use and   
 bullous lung disease in relatively  
 young users
Cancers
 • no conclusive evidence that   
 cannabis causes cancer
Immune function
 • evidence for the effects of   
 cannabis on human immune   
 function is limited
Complications in pregnancy
 • like tobacco, cannabis use in   
 pregnancy may be harmful to  
 foetal development; studies show  
 a consistent association between  
 cannabis use in pregnancy and  
 reduced birth weight – though  
 less so than as a result of tobacco  
 smoking during pregnancy
 • some reports that children born  
 to women who have used   
 cannabis in pregnancy may face  
 mild developmental problems;  
 however, the evidence is mixed  
 and confounded by the other  
 situational, health and lifestyle  
 factors and polysubstance use in  
 this population e.g. cannabis   
 users are more likely to use   
 tobacco, alcohol and other illicit  
 drugs during pregnancy 
Reproductive disorders
 • use can inhibit reproductive   
 functions and disrupt ovulation,  
 sperm production and sperm   
 function
Other complications
 • persistent sore throat
Organic/neurological
 • no evidence of structural change  
 in brains of heavy long term   
 cannabis users
 • no severe or grossly debilitating  
 impairment in cognitive function  
 (subtle impairment in higher   
 cognitive functions of memory,  
 learning processes, attention and  
 organization and the integration  
 of complex information – may or  
 may not be reversible after   
 abstinence)
Personality/mood
 • evidence that early initiation and  
 regular, heavy cannabis use is  
 associated with a small but   
 significantly increased risk of   
 psychotic symptoms and   
 disorders in later life
 • complex association between  
 cannabis use and schizophrenia  
 – some evidence that use may  
 exacerbate psychotic symptoms  
 and is linked with relapse but it is  
 unknown whether this is a   
 universal risk or due to   
 differences in individual   
 vulnerability
 • insomnia, depression, aggression,  
 anxiety
 • inconsistent and mixed evidence  
 for whether heavy, chronic   
 cannabis use is associated with a  
 persistent ‘amotivational   
 syndrome’ characterised by social  
 withdrawal and apathy
Dependence
 • good evidence for a cannabis  
 dependence syndrome
 • frequent, heavy users are at the  
 greatest risk of dependence
Withdrawal
 • irritability
 • anxious mood
 • physical changes (tremor,   
 perspiration and nausea)
 • sleep disturbance
Tolerance
 • tolerance to psychoactive and  
 physical effects unlikely to occur  
 unless there is sustained heavy  
 exposure
Synthetic cannabinoids
Withdrawal
 • some evidence of a withdrawal  
 syndrome among heavy users
Tolerance
 • suggestion that users may   
 develop tolerance quickly
5.2 Chronic adverse effects associated with the use of cannabis
5. Cannabis
*Studies of the harms associated with cannabis use are limited by confounding as many users smoke tobacco as well as cannabis, or use tobacco as vehicle for smoking 
cannabis resin. Although tobacco smoke and cannabis smoke are known to contain a similar range of mutagens and carcinogens, actual exposure to these compounds may 
differ between tobacco and cannabis users in terms of the frequency and duration of use, and because of factors such as the depth of inhalation
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Health harms of drugs
ROUTE OF 
ADMINISTRATION/
DOSE
COMBINATION USE 
(CONCURRENT USE, 
CONSECUTIVE USE)
AVAILABILITY/ 
PURITY
SOCIAL CONTEXT/ 
SETTING
AGE /
DEVELOPMENTAL 
ISSUES*
INDIVIDUAL 
VULNERABILITY LEGAL SITUATION
Route of 
administration
 • smoking
 • oral consumption  
 – makes dosage  
 difficult to  
 regulate and  
 unpleasant  
 reactions more  
 difficult to avoid
 • overall benefits  
 and harms of the  
 use of alternative  
 delivery systems  
 for inhalation,  
 such as through  
 vaporisation,  
 have not been  
 well studied
Dose
 • health effects of  
 increases in the  
 potency of  
 cannabis  
 products are not  
 clear; may  
 depend on the  
 impact on  
 routine use,  
 however there is  
 evidence of binge  
 use among some  
 users increasing  
 the risk of  
 dependence and  
 psychotic  
 symptoms
Concurrent use
 • smoking with  
 tobacco
Availability
 • three products  
 commonly  
 available  
 – cannabis resin  
 (hash), traditional  
 imported herbal  
 cannabis  
 (marijuana) and  
 typically higher  
 potency forms of  
 herbal cannabis  
 (e.g. sinsemilla,  
 ‘skunk’,   
 homegrown)
 • increase in  
 market share of  
 sinsemilla,  
 ‘skunk’, and  
 homegrown  
 forms of herbal  
 cannabis  
 suggests that  
 cannabis users  
 are now exposed  
 to higher  
 potency products
 • widely available  
 in the UK and  
 internationally
Social context
 • use has declined  
 over the last  
 decade
 • used across wide  
 range of social  
 and age contexts
 • perceived  
 therapeutic use  
 (pain relief,  
 anti-nausea)
 • possible self- 
 medication  
 among   
 psychiatric  
 patients; e.g.  
 people with  
 schizophrenia, or  
 its symptoms,  
 may use cannabis  
 to cope with the  
 negative  
 symptoms  
 associated with  
 schizophrenia, or  
 to suppress the  
 side-effects of  
 antipsychotic  
 medication
 • widely used by  
 opiate and crack  
 cocaine users
 • sole illicit drug  
 used by a  
 proportion of the  
 population
Developmental 
issues
 • suggestion that  
 regular use may  
 encourage users  
 to progress to  
 other forms of  
 drug abuse; the  
 likelihood of this  
 occurring is more  
 related to the  
 lifestyle and  
 personality of the  
 individual and  
 access to sources  
 of other illicit  
 drugs than the  
 effect of  
 cannabis itself
 • increased risk of  
 experiencing  
 psychotic  
 symptoms in  
 vulnerable  
 individuals e.g.  
 those with a  
 personal or  
 family history of  
 schizophrenia
 • use may  
 precipitate  
 relapse of  
 schizophrenia
 • use may  
 adversely affect  
 the course of  
 schizophrenia
 • stimulating  
 effects on the  
 cardiovascular  
 system of the  
 major   
 psychoactive  
 compound in  
 cannabis (THC)  
 can be   
 detrimental to  
 individuals with  
 cardiovascular or  
 respiratory  
 disease
Misuse of Drugs 
Act 1971
Class B
cannabis, cannabis 
resin, synthetic 
cannabinoids
5.3 Factors that mediate and moderate harms associated with the use of cannabis 
5. Cannabis
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6. Cocaine*
6.1 Acute adverse effects associated with the use of cocaine
PHYSICAL
PSYCHOLOGICAL/PSYCHIATRIC
MORTALITY MORBIDITY
Acute complications
 • toxic reactions (e.g. cardiovascular   
 complications) are not predicable from the  
 route of administration, quantity taken, an  
 individual’s pattern of drug use, or blood  
 concentrations of cocaine (or its metabolites)
 • injection of cocaine powder or crack cocaine  
 is associated with a greater risk of death than  
 infrequent, intranasal use of cocaine powder  
 alone; appears to be linked to factors   
 associated with injecting (such as more   
 frequent use and higher levels of cocaine  
 dependence) rather than the route of   
 administration per se
Vascular complications
 • abnormal heart rhythms (arrhythmias)
 • heart attack
 • inflammation and injury to the intestines  
 (mesenteric ischaemia)
 • stroke
Allergic reaction from intravenous use of 
cocaine
 • based on anecdotal citations – possibly caused 
 by additives in street cocaine
Excited delirium syndrome
 • characterised by hyperthermia, delirium and  
 agitation
 • associated with cardiac/respiratory arrest and  
 subsequent death
Cardiovascular complications
 • increase in blood pressure
 • accelerated heart rate 
 • abnormal heart rhythms (supraventricular/ 
 ventricular tachycardia, torsade de pointes)
 • increased risk of heart attack, particularly in  
 the first hour after use 
Respiratory complications
 • chest pain
 • shortness of breath
 • rapid breathing
Neurological complications
 • stroke
 • convulsions
Other complications
 • hyperthermia
 • muscle spasms, tremor
 • abdominal pain, nausea, vomiting
 • insufficient blood flow (ischaemia)
 • bleeding (haemorrhage)
 • liver damage
Genitourinary
 • increased sexual appetite and desire
Personality/mood
 • sleep disturbance
 • anxiety
 • paranoia
 • grandiosity
 • transient psychotic reactions
 • hallucinations (visual, auditory and tactile)  
 after large doses
 • aggression and possible violence (especially  
 associated with crack cocaine use)
*Cocaine hydrochloride (e.g. cocaine powder) and cocaine base (e.g. crack cocaine and freebase cocaine) 
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PHYSICAL
PSYCHOLOGICAL/PSYCHIATRIC DEPENDENCE/ WITHDRAWAL/ TOLERANCE
MORTALITY MORBIDITY
Cardiovascular complications
 • increased risk of cardiovascular  
 disease through toxic effects on  
 cardiovascular system (including  
 premature atherosclerosis,   
 vasospasm and thrombus   
 formation)
 • heart attack
 • heart failure
 • abnormal heart rhythms   
 (arrhythmias)
 • aortic dissection
 • inflammation and injury of the  
 heart muscle (endocarditis,   
 cardiomyopathy)
 • sudden death
Vascular complications
 • increased risk of cardiovascular  
 disease through toxic effects on  
 cardiovascular system
 • abnormally high blood pressure  
 in the arteries of the lungs   
 (pulmonary hypertension)
 • inflammation and injury of blood  
 vessels (vasculitis)
Neurological complications
 • stroke
 • inflammation and injury of the  
 blood vessels of the brain   
 (cerebral vasculitis)
Renal complications
 • kidney failure – commonly   
 associated with rhabdomyolysis
Lifestyle factors
 • anorectic effect – may contribute  
 to malnutrition and weight loss
 • chronic use diminishes sexual   
 appetite and ability – reversible  
 on stopping use 
Localised effects
 • dental erosions
 • perforation of the nasal septum
 • chronic rhinitis
 • loss of sense of smell
 • nosebleeds
Complications in pregnancy
 • premature rupture of the   
 membranes and placental   
 abruption associated with use  
 during pregnancy
 • effects of cocaine exposure may  
 persist into childhood; suggestion  
 that may impact on behaviour  
 problems, attention, language  
 and cognition
 • situational, health and lifestyle  
 factors and polysubstance use in  
 this population may also affect  
 pregnancy outcomes
Personality/mood
 • anxiety, depression
 • obsessional rituals/preoccupation, 
 repetitive behaviours
 • sleep disturbance (decrease in  
 quantity and quality of sleep)
 • irritability, restlessness
 • auditory hallucinations
 • paranoid delusions and psychosis
 • hyperexcitability
 • exhaustion
 • aggression and possible violence  
 (especially associated with crack  
 cocaine use)
Toxic syndrome
 • psychotic reaction similar to acute 
 paranoid schizophrenia and   
 psychoses with vivid auditory and  
 tactile hallucinations, picking and  
 excoriation of skin, delusions of  
 infection from parasites, paranoid  
 ideation
Neurological
 • studies have shown that chronic  
 cocaine use may contribute to  
 cognitive impairments in the   
 group of processes involved in  
 the learning, control and   
 monitoring of complex goal-  
 directed behaviour (executive  
 function)
 • may include deficits in memory  
 function and inhibitory control
Dependence
 • good evidence for a cocaine   
 dependence syndrome
 • a minority of users may  exhibit  
 cocaine dependence soon after  
 onset of cocaine use (in the first  
 1-2 years of use) – risk is greater  
 among those who smoke crack  
 cocaine and those who begin use  
 at an earlier age
Withdrawal
 • symptoms may be mild to   
 moderate but type and severity  
 vary from person to person:
– craving
– exhaustion/lack of energy,  
 fatigue
– over-eating
– depression
– low (dysphoric) mood
– unpleasant dreams
– insomnia or hypersomnia,  
 psychomotor retardation
– agitation, irritability
– anxiety, restlessness,
– aggression
Substance specific
Withdrawal
 • craving – possibly of a greater  
 magnitude for crack cocaine as  
 compared to that for cocaine   
 powder
6.2 Chronic adverse effects associated with the use of cocaine
6. Cocaine
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ROUTE OF 
ADMINISTRATION/
DOSE
COMBINATION USE 
(CONCURRENT USE, 
CONSECUTIVE USE)
AVAILABILITY/ 
PURITY
SOCIAL CONTEXT/ 
SETTING
AGE /
DEVELOPMENTAL 
ISSUES
INDIVIDUAL 
VULNERABILITY LEGAL SITUATION
Route of 
administration
 • higher acute risk  
 of death  
 associated with  
 injection of  
 cocaine or  
 smoking crack  
 cocaine than  
 intranasal use of  
 cocaine powder  
 –  due to rapid  
 increase in brain  
 levels of the drug  
 and route specific  
 factors
 • injection of crack  
 cocaine or  
 cocaine powder  
 – linked to risky  
 injecting practices 
  (such as frequent  
 injection), which  
 increase the risk  
 of acquiring HIV,  
 hepatitis C virus  
 and bacterial  
 infections
Concurrent use
 • a metabolite  
 (cocaethylene) is  
 formed following  
 concurrent use of  
 alcohol and  
 cocaine – toxic  
 effects of this  
 combination are  
 commonly seen  
 in cocaine related  
 deaths
 • concurrent use of  
 cocaine and  
 heroin (speedball)  
 frequently  
 mentioned in  
 fatal emergency  
 room admissions
Consecutive use
 • reports of use of  
 heroin after  
 cocaine to  
 manage negative  
 effects after  
 prolonged use 
 • chronic use of  
 cocaine may be a  
 risk factor for use  
 of heroin
Availability
 • last few years  
 have seen the  
 emergence of  
 cheaper, more  
 heavily   
 adulterated,  
 cocaine powder
 • when adjusted  
 for purity, the  
 price of cocaine  
 powder has  
 almost doubled  
 since 2003
Purity
 • relatively low  
 street level purity  
 of cocaine  
 powder and  
 crack cocaine  
 – mean 20% and  
 27% respectively  
 (2009 data)
Social context/
setting
 • cocaine powder  
 and crack  
 cocaine likely to  
 be used in very  
 different social  
 settings
 • crack cocaine use  
 most commonly  
 associated with  
 existing opiate  
 and crack  
 cocaine users
 • cocaine powder  
 more widespread  
 and used  
 functionally in  
 both employment  
 and social settings
Age
 • evidence that  
 early onset  
 (before age 18)  
 of other illicit  
 drug use (e.g.  
 cannabis)  
 increases  
 likelihood of  
 progression to  
 cocaine use 
 • for individuals  
 with pre-existing  
 ischaemic heart  
 disease, cocaine  
 can have an  
 apparently  
 sympathomimetic 
 effect on the  
 heart – increasing  
 myocardial  
 oxygen demands  
 to the extent that  
 angina pains  
 occur and  
 sometimes heart  
 attack
 • snorting or  
 smoking can  
 exacerbate  
 asthma
 • significant  
 exacerbating  
 effect on  
 individuals with  
 pre-existing  
 mental health  
 problems
Misuse of Drugs 
Act 1971
Class A
cocaine
 
6.3 Factors that mediate and moderate harms associated with the use of cocaine 
6. Cocaine
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7. The dissociative anaesthetics,    
 ketamine and phencyclidine*
7.1 Acute adverse effects associated with the use of dissociative anaesthetics
PHYSICAL
PSYCHOLOGICAL/PSYCHIATRIC
MORTALITY MORBIDITY
Acute complications
 • death is more often a result of accidents due  
 to loss of coordination/control, disassociation  
 and analgesia (e.g. jumping from heights,  
 road traffic accidents, drowning)
 • risk of respiratory depression
Ketamine
Acute complications
 • limited evidence base, but low risk of   
 mortality associated with the medicinal use of  
 ketamine 
 • rare reports of overdose deaths from heart  
 attack or respiratory problems
 • majority of fatalities have been attributed to  
 polysubstance use (multiple drug toxicity)
PCP
Acute complications
 • substantially more toxic than ketamine
 • death as a result of hyperthermia, convulsions
Acute intoxication
 • increased heart rate and respiration
 • loss of consciousness, coma
 • muscle jerking, repetitive movements,   
 outbursts (automatic behaviour)
 • gastric/stomach pain
 • many effects are polarised among users (i.e.  
 reports of opposing responses in different  
 individuals)
Ketamine
Injury
 • increased risk of injury from jumping from  
 heights, road traffic accidents and drowning;  
 associated with loss of coordination/  
 temporary paralysis and/or dissociative effects  
 (e.g. depersonalisation, derealisation and  
 reduced perception of pain) 
PCP
Acute intoxication
 • increase in body temperature (hyperthermia)
 • stroke
 • respiratory arrest
 • nausea, vomiting
 • loss of coordination (ataxia)
 • hypersalivation
Organic/neurological
 • hallucinations, distorted sensory perception
 • impaired attention, memory and learning
 • altered body perception
 • impairments of cognitive function and verbal  
 fluency
Personality/mood
 • confusion
 • depersonalisation
 • derealisation
 • panic attacks, agitation, paranoia
 • delirium
 • depression
 • night terrors
 • behavioural effects resembling certain   
 symptoms of schizophrenia
 • extreme loss of motor skills (catatonia)
PCP
Organic/neurological
 • toxic psychosis (catatonia or paranoia)
*Ketamine and phencyclidine (PCP)
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PHYSICAL
PSYCHOLOGICAL/PSYCHIATRIC DEPENDENCE/ WITHDRAWAL/ TOLERANCE
MORTALITY MORBIDITY
 • very low risk of mortality Ketamine
Chronic complications
 • ketamine-induced ulcerative   
 cystitis (marked thickening of the  
 bladder wall and severe   
 inflammation) has been described  
 in clinical case reports; only   
 following heavy use
 • vague abdominal pains (gastritis)
PCP
Chronic complications
 • no human evidence to suggest  
 long term physical damage
 • evidence from animal studies of  
 congenital malformations and  
 reproductive disorders
Organic/neurological
 • memory impairment
 • prolonged hallucinations,   
 flashbacks, persistent perceptual  
 changes
Personality/mood
 • night terrors
 • evidence of triggering depression  
 post traumatic stress disorder,  
 mania in susceptible individuals
 • may aggravate psychotic   
 symptomatology
Ketamine
Organic/neurological
 • evidence from animal studies   
 suggests that ketamine may   
 accelerate nerve cell death in the  
 brain – no evidence that such an  
 effect occurs in humans
 • some evidence of cognitive   
 impairments among regular,   
 heavy users
PCP
Personality/mood
 • anorexia
 • insomnia
 • auditory hallucinations
 • disorientation
 • paranoid delusions
Ketamine
Dependence
 • there have been few published  
 reports of ketamine dependence,  
 however, cases have been noted  
 among regular, heavy users
Withdrawal
 • no evidence to suggest   
 withdrawal symptoms or   
 syndrome
Tolerance
 • evidence to support the rapid  
 development of tolerance over  
 regular repeated dosing
PCP
Dependence
 • evidence to suggest a   
 dependence syndrome for PCP
Withdrawal
 • some evidence to suggest   
 withdrawal syndrome
 • craving
 • increased appetite
 • hypersomnia
 • depression
7.2 Chronic adverse effects associated with the use of dissociative anaesthetics
7. The dissociative anaesthetics,    
 ketamine and phencyclidine*
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ROUTE OF 
ADMINISTRATION/
DOSE
COMBINATION USE 
(CONCURRENT USE, 
CONSECUTIVE USE)
AVAILABILITY/ 
PURITY
SOCIAL CONTEXT/ 
SETTING
AGE /
DEVELOPMENTAL 
ISSUES
INDIVIDUAL 
VULNERABILITY LEGAL SITUATION
Ketamine
Route of 
administration
 • intranasal use is  
 most popular 
 • by injection,  
 among long- 
 term users
Dose
 • street dose is  
 approximately  
 10-25% of the  
 general   
 anaesthetic dose  
 (1 to 2 mg/kg  
 racemic ketamine)
 • influence of set  
 and setting has  
 greater impact at  
 a lower (street)  
 dose
 • as dose increases  
 pharmacological  
 properties of the  
 drug override the  
 effect of set and  
 setting
 • ketamine has a  
 short half life and  
 thus regular,  
 sequential dosing  
 occurs, thereby  
 increasing related  
 risks
PCP
Route of 
administration
 • smoked
Concurrent use
 • ketamine may  
 commonly be  
 used with other  
 stimulants or  
 alcohol 
 • suggestion that  
 the dissociative  
 effects of  
 ketamine may  
 make users less  
 aware of the  
 effects of  
 respiratory  
 depression  
 caused by other  
 drug use (e.g.  
 alcohol or  
 opioids)
Ketamine
Availability
 • majority found  
 on the illicit  
 market is  
 diverted from  
 legitimate  
 sources
 • may be sold as  
 MDMA in clubs
PCP
Availability
 • often taken  
 unknowingly  
 when sold in  
 other illicit drugs
 • abuse not  
 considered to  
 have ever been a  
 major problem in  
 the UK
Ketamine
Social context
 • has emerged as a  
 mainstream club  
 drug in recent  
 years
 • has been  
 marketed in clubs  
 as a ‘quick, fun  
 high’ but  
 dissociative  
 effects may  
 prove disturbing  
 for the   
 inexperienced  
 user
 • distinct   
 subculture of  
 older ketamine  
 users has been  
 identified   
 – tendency for  
 injecting use and  
 use to achieve  
 “greater  
 understanding of  
 the self or  
 universe”
PCP
Setting
 • overcrowding  
 and heat in  
 dance   
 environment may  
 increase risk for  
 hyperthermia
 • Not documented, 
  limited evidence  
 base
 • individual  
 vulnerability for  
 acute physical  
 problems  
 – previous history  
 of epilepsy,  
 cardiovascular or  
 cerebrovascular  
 disease
 • psychological  
 vulnerability  
 increased with  
 previous or  
 current history of  
 psychiatric illness,  
 or family history
Misuse of Drugs 
Act 1971
Class A
PCP
Class C
ketamine
7.3 Factors that mediate and moderate harms associated with the use of dissociative anaesthetics 
7. The dissociative anaesthetics,    
 ketamine and phencyclidine*
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8. Gamma-hydroxybutyrate and    
 gamma-butyrolactone*
8.1 Acute adverse effects associated with the use of GHB, GBL or 1,4-BD
PHYSICAL
PSYCHOLOGICAL/PSYCHIATRIC
MORTALITY MORBIDITY
Acute complications
 • loss of consciousness – difficult to get dose  
 right and solutions of GHB often vary in   
 concentration
 • deaths solely caused by GHB appear to be  
 rare – fatalities appear to be mostly in   
 combination with alcohol or other central  
 nervous system depressants 
Acute intoxication
 • loss of consciousness
 • coma
 • respiratory and cardiac depression, bradycardia
 • hypothermia
 • nausea, vomiting
 • seizures
 • confusion
 • involuntary muscle twitching or spasm   
 (myoclonus, dystonia)
 • breathing difficulties
 • agitation
 • Limited evidence for the psychological/  
 psychiatric effects of GHB, GBL and 1,4-BD
Personality/mood
 • agitation
 • combativeness
*Gamma-hydroxybutyrate (GHB), gamma-butyrolactone (GBL) and 1,4 butanediol (1,4-BD)
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PHYSICAL
PSYCHOLOGICAL/PSYCHIATRIC DEPENDENCE/ WITHDRAWAL/ TOLERANCE
MORTALITY MORBIDITY
Withdrawal
 • severe cases of withdrawal,   
 including fatalities have been   
 reported
 • not documented  • not documented Dependence
 • evidence of a dependence   
 syndrome associated with  heavy,  
 frequent use
 • no dependence syndrome has  
 been observed at low doses of  
 GHB
Withdrawal
 • examples in the literature of   
 physical dependence evidenced  
 by a withdrawal syndrome
 • anxiety
 • insomnia
 • increased heart rate (tachycardia)
 • hallucinations, delirium and   
 psychosis
 • sweating
 • aches
 • abdominal pain
 • impotence
 • severe depression
 • reports of severe withdrawal   
 symptoms (e.g. rapid onset of  
 delirium) associated with   
 unplanned detoxification
8.2 Chronic adverse effects associated with the use of GHB, GBL or 1,4-BD
8. Gamma-hydroxybutyrate and    
 gamma-butyrolactone
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ROUTE OF 
ADMINISTRATION/
DOSE
COMBINATION USE 
(CONCURRENT USE, 
CONSECUTIVE USE)
AVAILABILITY/ 
PURITY
SOCIAL CONTEXT/ 
SETTING
AGE /
DEVELOPMENTAL 
ISSUES
INDIVIDUAL 
VULNERABILITY LEGAL SITUATION
Route of 
administration
 • prepared as a  
 liquid
 • small alterations  
 in the   
 manufacture of  
 illicit GHB can  
 result in the  
 synthesis of GBL 
Dose
 • toxicity is dose  
 dependent  
 – small increase  
 in dose can cause  
 severe harms
 • GBL is absorbed  
 more rapidly  
 than GHB and  
 has a faster onset  
 of action
Concurrent use
 • use often  
 involves  
 concurrent use of  
 other drugs such  
 as alcohol or  
 MDMA
 • in combination  
 with alcohol  
 – associated with  
 increased  
 agitation and  
 aggressive  
 behaviour
 • overdose in  
 combination with  
 stimulants has  
 been associated  
 with deeper,  
 more prolonged  
 coma, and longer  
 recovery times
Availability
 • suggestion that  
 GBL may be  
 more easily  
 acquired than  
 GHB – use of  
 GHB precursor  
 chemicals is still  
 allowed in  
 products in the  
 chemical industry 
Social context/
setting
 • evidence of use  
 among body- 
 builders for  
 proposed  
 anabolic effects,  
 although this  
 category of users  
 has decreased in  
 recent years
 • emergence as a  
 recreational drug  
 is a relatively  
 recent   
 phenomenon;  
 earliest reports of  
 use date back to  
 the 1990’s
 • the use of GHB  
 precursor  
 chemicals, GBL  
 and to a lesser  
 extent 1,4-BD  
 has increased  
 over the last few  
 years
 • not documented  • not documented Misuse of Drugs 
Act 1971
Class C
GHB, GBL and 
1,4-BD
8.3 Factors that mediate and moderate harms associated with the use of GHB, GBL or 1,4-BD 
8. Gamma-hydroxybutyrate and    
 gamma-butyrolactone
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9. Serotonergic hallucinogens*
PHYSICAL
PSYCHOLOGICAL/PSYCHIATRIC
MORTALITY MORBIDITY
Acute complications
 • risk of injury and accidental death due to  
 perceptual distortions and impaired decision  
 making
LSD
Acute complications
 • one case of fatal overdose has been reported  
 in the literature; associated with a high dose  
 of LSD
Psilocybin 
Acute complications
 • fatal poisoning due to mistaken identity of  
 mushrooms
Violence and injuries
 • self harm, accidents or violence while   
 intoxicated
LSD
Common effects
 • adrenergic `fight or flight` effects
 • tachycardia
 • flushing
 • dry mouth
 • sweating
 • exhaustion, tiredness, weakness 
Rare effects
 • ataxia
 • convulsions
 • hyperpyrexia
Psilocybin
 Acute intoxication
 • nausea, vomiting, stomach pains – commonly  
 due to mistaken identity of mushrooms
 • dizziness
DMT
Acute intoxication
 • nausea and vomiting
Personality/mood
 • dysphoria
 • unpleasant distortions in shapes and colours
 • frightening illusions, delusions; ‘true   
 hallucinations’ in psychiatric terms (i.e.   
 indicative of psychiatric morbidity) are very  
 rare
 • anxiety, panic, depression
 • dizziness, disorientation
 • impaired concentration
 • frequent mood changes (emotional lability)
 • recall of psychologically troubling memories
 • depersonalisation and derealisation at high  
 doses
 • short lived psychotic episode (hallucinations,  
 paranoia)
 • precipitates relapses in schizophrenia
9.1 Acute adverse effects associated with the use of serotonergic hallucinogens
*Lysergic acid diethylamide (LSD), psilocybin, mescaline and N,N-dimethyltryptamine (DMT)
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PHYSICAL
PSYCHOLOGICAL/PSYCHIATRIC DEPENDENCE/ WITHDRAWAL/ TOLERANCE
MORTALITY MORBIDITY
 • limited evidence base  • no known physical dangers   
 associated with long-term LSD  
 use
Personality/mood* 
 • persistence of low-level   
 hallucinations, known as   
 hallucinogen persisting   
 perception disorder – rare
 • brief flashbacks or recollection of  
 previous hallucinatory experience  
 may occur days or months after  
 use
 • depression
 • feelings of isolation
 • delirium
Psychosis
 • uncertain whether drug induced  
 condition or unmasking of a   
 latent mental illness
Dependence
 • evidence suggests that few users  
 of hallucinogens experience signs  
 or symptoms of dependence
Withdrawal
 • a withdrawal syndrome has not  
 been identified
Tolerance
 • tolerance develops rapidly to   
 behavioural effects and sensitivity  
 returns after comparable drug  
 free interval, tolerance to   
 cardiovascular effects less   
 pronounced
 • cross tolerance between   
 serotonergic hallucinogens
9.2 Chronic adverse effects associated with the use of serotonergic hallucinogens
9. Serotonergic hallucinogens
*Post-exposure
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Health harms of drugs
ROUTE OF 
ADMINISTRATION/
DOSE
COMBINATION USE 
(CONCURRENT USE, 
CONSECUTIVE USE)
AVAILABILITY/ 
PURITY
SOCIAL CONTEXT/ 
SETTING
AGE/
DEVELOPMENTAL 
ISSUES*
INDIVIDUAL 
VULNERABILITY LEGAL SITUATION
Psilocybin 
Route of 
administration
 • poisoning due to  
 mistaken identity  
 of mushrooms
Concurrent use
 • may be   
 combined with  
 MDMA to  
 heighten physical  
 sensations
 • oral DMT may be  
 combined with a  
 variety of natural  
 and synthetic  
 monoamine  
 oxidase inhibitors  
 to simulate  
 ayahuasca (an  
 Amazonian  
 'plant medicine')
Availability
 • seasonal and  
 localised  
 availability of  
 mushrooms
 • LSD generally  
 available; use has  
 declined over last  
 few years
 • mescaline and  
 DMT rarely  
 available
Purity
 • purity data not  
 commonly  
 available
Setting
 • risk of injury  
 when consumed  
 alone in  
 potentially  
 dangerous  
 locations – e.g.  
 near water (risk  
 of drowning), on  
 a high building  
 (risk of falls)
Age
 • noted as a drug  
 of early   
 experimentation,  
 but not of  
 long-term use
 • psychosis as a  
 result of chronic  
 use – uncertain  
 whether drug  
 induced  
 condition or  
 unmasking of a  
 latent mental  
 illness
Misuse of Drugs 
Act 1971
Class A
LSD, psilocybin, 
DMT, mescaline
9.3 Factors that mediate and moderate harms associated with the use of serotonergic hallucinogens 
9. Serotonergic hallucinogens
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10. Nitrites*
10.1 Acute adverse effects associated with the use of nitrites
PHYSICAL
PSYCHOLOGICAL/PSYCHIATRIC
MORTALITY MORBIDITY
Acute complications
 • death may be caused by a lack of oxygen  
 (hypoxia) resulting in severe injury to red  
 blood cells and reduction in the  supply of  
 oxygen to vital organs
 • may lose consciousness and die through  
 choking on own vomit
 • 'sudden sniffing death syndrome' fatality  
 caused by abnormal heart rhythms (cardiac  
 arrhythmia)
 • some cases of death reported from direct oral  
 consumption of nitrites
Acute intoxication
 • nausea
 • headache
 • loss of consciousness, sedation, anaesthesia
 • loss of coordination (ataxia), weakness (less  
 common)
Lifestyle factors
 • associated with high risk sexual practices
Cardiovascular complications
 • profound hypotension (low blood pressure)
 • rebound tachycardia
 • flushed skin followed by vasoconstriction
Other complications
 • rash around nose and mouth and contact  
 dermatitis
 • irritation of the nose and throat
 • increased ocular pressure, blurred vision
Personality/mood
 • disorientation
 • distorted perceptions
 • delirium
*Amyl nitrite, butyl nitrite and isobutyl nitrite
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PHYSICAL
PSYCHOLOGICAL/PSYCHIATRIC DEPENDENCE/ WITHDRAWAL/ TOLERANCE
MORTALITY MORBIDITY
Carcinogenic properties
 • use produces nitrosamine which  
 is carcinogenic – however still to  
 be determined whether formed  
 in sufficient quantities to make  
 the risk clinically significant
Lifestyle factors
 • by facilitating unsafe sexual   
 practices some evidence that use  
 indirectly increases susceptibility  
 to Kaposi’s sarcoma in people  
 who are HIV positive 
Immune function
 • limited evidence that   
 immunologic function may be  
 suppressed – use of nitrites has  
 been associated with facilitating  
 the transmission of HIV
Chronic medical problems
 • rash and irritation around the   
 nose, mouth or other exposed  
 areas
 • sinusitis
Blood-related (haematological) 
complications
 • anaemia
 • difficulty circulating oxygen   
 through the blood stream   
 (methaemoglobinaemia)
Organic/neurological
some evidence to suggest 
impairment to:
 • cognition
 • movement
 • vision
 • hearing
Dependence
 • no evidence for a dependence  
 syndrome
Withdrawal
 • no withdrawal syndrome   
 documented
Tolerance
 • evidence to suggest chronic,   
 regular users may develop   
 tolerance
10.2 Chronic adverse effects associated with the use of nitrites
10. Nitrites
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ROUTE OF 
ADMINISTRATION/
DOSE
COMBINATION USE 
(CONCURRENT USE, 
CONSECUTIVE USE)
AVAILABILITY/ 
PURITY
SOCIAL CONTEXT/ 
SETTING
AGE/
DEVELOPMENTAL 
ISSUES
INDIVIDUAL 
VULNERABILITY LEGAL SITUATION
Route of 
administration
 • inhaled –  
 substance is an  
 irritant
Concurrent use
 • use with alcohol  
 and other central  
 nervous system  
 depressants may  
 increase the risk  
 of asphyxiation  
 and death
 • anecdotal  
 evidence to  
 suggest may be  
 used to increase  
 the effects of  
 other drugs, such  
 as cannabis  or  
 MDMA
 • in combination  
 with drugs used  
 to treat erectile  
 dysfunction (e.g.  
 Viagra) – causes  
 abnormally low  
 blood pressure
Availability
 • amyl nitrite  
 available on grey  
 market
 • also available in  
 shops and on  
 mail order; may  
 be sold as room  
 odouriser
Social context
 • associated with  
 risky sexual  
 behaviour  
 leading to  
 increased risk of  
 exposure to  
 sexually  
 transmitted  
 infections 
Setting
 • risk of injury  
 when consumed  
 alone in  
 potentially  
 dangerous  
 locations – e.g.  
 near water (risk  
 of drowning), on  
 a high building  
 (risk of falls)
Age
 • used mainly by  
 older adolescents  
 and adults, to  
 enhance sexual  
 function or the  
 effects of other  
 drugs
 • people with HIV 
 • people with poor  
 general physical  
 health
 • people with  
 ocular conditions,  
 particularly  
 glaucoma
Not controlled 
under the Misuse 
of Drugs Act 1971
Amyl nitrite is 
regulated under 
the Medicines Act 
1968
 
10.3 Factors that mediate and moderate harms associated with the use of nitrites 
10. Nitrites
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11. Novel synthetic drugs*
11.1 Acute adverse effects associated with the use of novel synthetic drugs
PHYSICAL
PSYCHOLOGICAL/PSYCHIATRIC
MORTALITY MORBIDITY
Acute complications
 • substituted cathinones (primarily   
 mephedrone) have been implicated in deaths  
 in England and Scotland – however, with a  
 limited evidence base the exact role of   
 cathinones in causing or contributing to death  
 is still to be determined
 • one case of fatal overdose reported in the  
 international literature relating to the use of  
 2C series phenethylamines
 • one case of fatal overdose reported in the  
 international literature relating to the use of  
 tryptamine derivatives
Acute intoxication
 • few clinical data available for novel synthetic  
 drugs, most data regarding harms are   
 self-reported
 • chest pain is common feature of acute   
 intoxication
Substituted cathinones and piperazines
Acute intoxication
 • consistent with sympathomimetic toxicity
– agitation
– palpitations
– seizure
– vomiting
– sweating
– headache
– reduced appetite
– severe vasoconstriction of extremities,  
 leading to bluing of fingers or hands  
 (cathinone users)
2C series phenethylamines
Neurological complications
 • one case of damage to the blood vessels in  
 the brain associated with persistent neurologic  
 deficits reported in the international literature
Tryptamine derivatives
 • not documented, limited evidence base
Substituted cathinones and piperazines
Personality/mood
 • consistent with sympathomimetic toxicity
– mood swings
– anxiety
– strange thoughts
– irritability, confusion
Substituted cathinones
Organic/neurological
 • high doses may be associated with   
 hallucinations and psychosis
2C series phenethylamines
Organic/neurological
 • one case of acute intoxication associated with  
 psychosis reported in the international   
 literature
Tryptamine derivatives
Organic/neurological
 • hallucinations
*Substituted cathinones, piperazines, 2C series phenethylamines and tryptamine derivatives
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PHYSICAL
PSYCHOLOGICAL/PSYCHIATRIC DEPENDENCE/ WITHDRAWAL/ TOLERANCE
MORTALITY MORBIDITY
 • not documented  • not documented  • not documented Substituted cathinones and 
piperazines
Dependence
 • suggestion that similar to   
 amphetamine in terms of abuse  
 and dependence potential
Tolerance
 • some evidence to suggest that  
 substituted cathinone users may  
 develop tolerance quickly
11.2 Chronic adverse effects associated with the use of novel synthetic drugs
11. Novel synthetic drugs
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ROUTE OF 
ADMINISTRATION/
DOSE
COMBINATION USE 
(CONCURRENT USE, 
CONSECUTIVE USE)
AVAILABILITY/ 
PURITY
SOCIAL CONTEXT/ 
SETTING
AGE/
DEVELOPMENTAL 
ISSUES
INDIVIDUAL 
VULNERABILITY LEGAL SITUATION
Substituted 
cathinones
Route of 
administration
 • may be snorted  
 or swallowed  
 (often after  
 wrapping in  
 tissue paper)
 • rare cases of  
 substituted  
 cathinones being  
 injected
Tryptamines
Route of 
administration
 • majority taken  
 non-orally i.e.  
 injected, snorted,  
 or smoked)
 • 5-MeO-DIPT  
 may be taken  
 orally
Concurrent use
 • suggestion that  
 novel synthetics  
 are sometimes  
 used in   
 conjunction with  
 alcohol or other  
 drugs, including  
 cocaine,  
 cannabis,  
 ketamine and  
 MDMA
 • suggestion that  
 novel synthetics  
 are sometimes  
 used as   
 substitutes for  
 cocaine,  
 hallucinogens,  
 ketamine and  
 MDMA;  
 particularly when  
 drug is legal
Availability/purity
 • limited evidence  
 base
 • suggestion that  
 piperazines (e.g.  
 BZP) and  
 synthetic  
 cathinones are  
 being used as  
 substitutes for  
 MDMA in  
 ecstasy tablets
 • not documented  • not documented  • not documented Misuse of Drugs 
Act 1971
Class A
tryptamines, 2C 
series 
phenethylamines
Class B
cathinone 
derivatives
Class C
piperazines
 
11.3 Factors that mediate and moderate harms associated with the use of novel synthetic drugs 
11. Novel synthetic drugs
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12. Opioids*
12.1 Acute adverse effects associated with the use of illicit opioids and abuse of prescription opioids
PHYSICAL
PSYCHOLOGICAL/PSYCHIATRIC
MORTALITY MORBIDITY
Overdose
 • respiratory depression and drop in blood  
 pressure resulting in respiratory arrest 
 • illicit opioid use is associated with the majority  
 of illicit drug-related deaths in the UK,   
 primarily from overdose
Common correlates of overdose fatality
 • long history of opioid dependence
 • high level of opioid dependence
 • recent abstinence (e.g. prison, detoxification  
 release)
 • polydrug use (particularly with alcohol and  
 benzodiazepines)
 • being male
 • increasing age (most fatalities occur among  
 those in their 30’s)
 • social isolation
 • neurocognitive deficits
 • while drug treatment generally provides a  
 protective effect, there is a significantly   
 enhanced risk in the first two weeks of   
 methadone treatment, following   
 detoxification treatment and on cessation of  
 naltrexone treatment
 • recent abstinence on release from prison
Common features of acute intoxication
 • nausea, vomiting
 • depressed nervous system activity
 • constipation
 • drowsiness, decreased consciousness
 • sedation, mental confusion
Infrequent features of acute intoxication
 • sweating
 • facial flushing
 • itching (pruritus)
 • dry mouth
 • hallucinations
 • dysphoria
 • difficulty in passing urine (urinary retention)
Rare features of acute intoxication
 • complications associated with non fatal   
 overdose e.g. hypoxia causing brain damage
 • disease of the white matter of the brain   
 (leukoencephalopathy) resulting from   
 inhalation of heroin vapours that does not  
 seem to occur with injection; sporadic reports  
 of cases in the literature
Prescription drugs
Serotonin syndrome
 • few cases of tramadol use associated with  
 serotonin syndrome, a potentially life   
 threatening condition, have been reported in  
 the literature
 • no acute psychological adverse effects 
 • cause little psychomotor or cognitive   
 impairment in tolerant user
*Including illicit (i.e. heroin) and prescription (e.g. methadone, buprenorphine, tramadol, dihydrocodeine and oxycodone) opioids
53
Health harms of drugs
PHYSICAL
PSYCHOLOGICAL/PSYCHIATRIC DEPENDENCE/ WITHDRAWAL/ TOLERANCE
MORTALITY MORBIDITY
Overdose
• increased mortality risk from   
 overdose and route specific   
 hazards
Suicide
• suicide rate higher than general  
 population; associated with   
 situational, health and lifestyle  
 factors
Chronic complications
• non-injected opioids carry little  
 risk of chronic adverse health   
 effects
• chronic constipation
• dry mouth
• menstrual irregularity
• malnutrition, anorexia; associated  
 with situational, health and   
 lifestyle factors
• tooth decay
• decreased sexual desire and   
 performance
Respiratory complications
• respiratory diseases (asthma,   
 chronic obstructive pulmonary  
 disease)
Hormones and immune function
• modest suppression of hormone  
 levels
• suppression of immune system,  
 social deprivation and   
 malnutrition may also be factors
Complications in pregnancy
• intrauterine growth of the foetus  
 may be inhibited
• newborns exposed to illicit   
 opioids may have  low birth   
 weight compared to non-  
 exposed children, be born   
 prematurely, and experience   
 respiratory depression and   
 withdrawal symptoms – these  
 symptoms may contribute to the  
 increased risk of perinatal   
 mortality associated with use of  
 illicit opioids in pregnancy 
• evidence for a direct effect of  
 illicit opioids is confounded by  
 other situational, health and   
 lifestyle factors (e.g. use of other  
 drugs, mother’s nutritional status,  
 lifestyle, infections and exposure  
 to trauma) that may be at least as  
 decisive for the outcome of the  
 pregnancy
• suggestion that a deprived social  
 environment may also contribute  
 to problems with neurological  
 developments
Personality/mood
• depressive disorder is common  
 among those dependent on   
 opioids but difficult to attribute  
 causality
• instability of mood
• lethargy
• opiates are not causally linked to  
 chronic psychiatric disorders
Dependence
 • characterised by profound   
 psychological and physical   
 dependence
 • develops after repeated   
 administration over a period of  
 time, which varies according to  
 the quantity, frequency and route  
 of administration – factors of   
 individual vulnerability and the  
 context of drug use also play a  
 role
Withdrawal
 • rarely life threatening
 • dependent on opioid used, dose,  
 route of administration, the   
 interval between doses, duration  
 of use, and users’ physical and  
 psychological health 
 • symptoms include watery eyes,  
 nasal discharge, yawning,   
 sweating, sleep disturbance,   
 dilated pupils, anorexia,   
 gooseflesh, restlessness,   
 irritability, tremor, sneezing,   
 weakness, depression, nausea,  
 vomiting, abdominal cramps,   
 muscle spasms and diarrhoea
Tolerance
 • characterised by shortened   
 duration and decreased intensity  
 of drug’s depressant effects,   
 marked elevation in average   
 lethal dose
12.2 Chronic adverse effects associated with the use of illicit opioids and abuse of prescription opioids
12. Opioids
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Health harms of drugs
ROUTE OF 
ADMINISTRATION/
DOSE
COMBINATION USE 
(CONCURRENT USE, 
CONSECUTIVE USE)
AVAILABILITY/ 
PURITY
SOCIAL CONTEXT/ 
SETTING
AGE/
DEVELOPMENTAL 
ISSUES
INDIVIDUAL 
VULNERABILITY LEGAL SITUATION
Route of 
administration
 • opioids in various  
 formulations may  
 be prepared for  
 injection –  
 particular  
 problems may  
 arise from  
 injection of  
 non-parenteral  
 preparations (e.g.  
 liquid   
 preparations or  
 tablets)
 • heroin may be  
 smoked –  
 increases risk of  
 respiratory  
 diseases including 
 asthma and  
 chronic   
 obstructive  
 pulmonary  
 disorder
Concurrent use
 • increased risk of  
 overdose if used  
 in combination  
 with alcohol,  
 benzodiazepines  
 or other CNS  
 depressants
 • cyclizine (an  
 antiemetic) used  
 in combination  
 with methadone  
 and other opioids  
 causes   
 disorientation,  
 gross intoxication
Availability
 • heroin has  
 decreased in  
 price in the UK  
 since 2003 
 • methadone is  
 widely available  
 on prescription  
 and as a result  
 may be sold  
 illicitly in the UK;  
 the size of the  
 illicit market is  
 unknown
Purity
 • mean purity of  
 heroin has  
 remained  
 relatively stable  
 since 2003  
 – mean 44%  
 (2009 data) 
 • limited evidence  
 for fatal  
 anaphylactoid  
 shock, but may   
 arise from an  
 acute allergic  
 response to illicit  
 heroin (either to  
 the drug itself or  
 to adulterants)
Setting
 • injection of  
 opioids when  
 alone increases  
 the risk of fatal  
 overdose as no  
 one is present to  
 resuscitate or get  
 help
 • slow onset of  
 methadone may  
 induce naive  
 users and those  
 new to drug  
 treatment to  
 increase dose  
 leading to  
 overdose  
 (particularly  
 related to  
 polysubstance  
 use)
 • increased risk of  
 overdose on  
 induction into  
 methadone  
 treatment due to  
 pharmacokinetics  
 of methadone 
 • tolerance  
 decreases after  
 abstinence and  
 individuals are at  
 increased risk of  
 overdose  
 following  
 cessation of  
 treatment or on  
 release from  
 prison
Age
• increase in heroin  
 use among  
 young people in  
 England and  
 Wales in the mid  
 1990s; however,  
 use remains rare  
 among this age  
 group
• some people may  
 have a genetic  
 vulnerability that  
 increases the  
 likelihood of  
 dependence on  
 opioids
Misuse of Drugs 
Act 1971
Class A
fentanyl, heroin, 
methadone, 
morphine, 
oxycodone 
Class B
dihydrocodeine, 
codeine
Class C
buprenorphine
Not controlled but 
regulated under 
Medicines Act 
1968
tramadol 
12.3 Factors that mediate and moderate harms associated with the use of illicit opioids and abuse of prescription opioids 
12. Opioids
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13. Over-the-counter products*
PHYSICAL
PSYCHOLOGICAL/PSYCHIATRIC
MORTALITY MORBIDITY
Dextromethorphan
Acute complications
 • ingestion of large amounts has been   
 associated with death through respiratory  
 depression
Codeine-containing products
Acute complications
 • risk of death as a consequence of   
 paracetamol, aspirin or ibuprofen overdose
Dextromethorphan
Acute intoxication
 • increased heart rate
 • elevated blood pressure
 • increased body temperature (hyperthermia)
 • loss of coordination (ataxia), dizziness
 • nausea and vomiting
 • restlessness
 • slurred speech
 • tremor
 • involuntary eye movements (nystagmus),  
 blurred vision
Codeine-containing products
Acute complications
 • adverse effects are similar to the those seen  
 with other opioids (see Table 12.1), but may  
 vary in intensity
 • complications relating to toxicity of   
 paracetamol, aspirin or ibuprofen; including  
 liver damage, renal failure and gastric bleeds 
Dextromethorphan
Organic/neurological
 • psychosis and mania associated with high  
 doses 
Personality/mood
 • lethargy, sleepiness or insomnia
 • confusion
13.1 Acute adverse effects associated with the use of over-the-counter (OTC) products
*Including dextromethorphan and codeine-containing products
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PHYSICAL
PSYCHOLOGICAL/PSYCHIATRIC DEPENDENCE/ WITHDRAWAL/ TOLERANCE
MORTALITY MORBIDITY
Dextromethorphan
• rare case of death following   
 overdose associated with choking  
 on own vomit
Codeine-containing products
• risk of death as a consequence of  
 paracetamol, aspirin or ibuprofen  
 overdose
Dextromethorphan
Respiratory complications
 • respiratory depression
Codeine-containing products
Toxicity related to paracetamol, 
aspirin or ibuprofen overdose
 • several cases of low blood   
 potassium (hypokalaemia)   
 secondary to an ibuprofen-  
 induced kidney disorder (renal  
 tubule acidosis) 
 • cases of perforated gastric ulcers  
 associated with combination   
 ibuprofen-codeine preparations
Dextromethorphan
Organic/neurological
 • cases of psychosis and mania   
 associated with high doses of  
 dextromethorphan reported in  
 the international literature
Dextromethorphan
Withdrawal
 • withdrawal symptoms described  
 include craving for the drug,   
 insomnia, somnambulism,   
 lethargy, dysphoria, depression  
 and ataxia
Codeine-containing products
Dependence
 • effects of combination product in  
 addition to codeine are likely to  
 be a contributory factor in   
 dependence
13.2 Chronic adverse effects associated with the use of OTC products
13. Over-the-counter products
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ROUTE OF 
ADMINISTRATION/
DOSE
COMBINATION USE 
(CONCURRENT USE, 
CONSECUTIVE USE)
AVAILABILITY/ 
PURITY
SOCIAL CONTEXT/ 
SETTING
AGE/
DEVELOPMENTAL 
ISSUES*
INDIVIDUAL 
VULNERABILITY LEGAL SITUATION
Dextromethorphan
Route of 
administration
 • taken orally
Dose
 • at high doses  
 converted to the  
 active metabolite, 
 dextrophan;  
 similar effects to  
 those associated  
 with ketamine  
 and PCP
 • ‘plateaus’ of  
 effect have been  
 described by  
 recreational users
 • full dissociative  
 phase occurs at  
 doses 40-100  
 times greater  
 than the cough  
 suppressant dose  
 (10 to 20 mg up  
 to 4 times per  
 day) 
Codeine-containing 
products
Route of 
administration 
 • taken orally
 • reports of  
 products being  
 reformulated by  
 users to extract  
 codeine part 
Concurrent use
 • toxicity arising  
 from   
 combination  
 products e.g.  
 aspirin,   
 paracetamol and  
 ibuprofen
Dextromethorphan
Availability
 • over-the-counter  
 cough medicine
Codeine-containing 
products
Availability
 • over-the-counter  
 analgesic and  
 cough   
 suppressant
 • pack sizes  
 recently limited  
 to 32 tablets in  
 the UK
Social context
 • abuse of OTC  
 products may be  
 associated with  
 intentional  
 misuse, or it may  
 develop  
 secondary to  
 dependence that  
 has developed as  
 a result of  
 legitimate use;  
 the size of the  
 problem is  
 unknown
 • not documented Dextromethorphan
 • limited data  
 suggest that  
 ‘poor   
 metabolisers’  
 experience  
 greater dysphoric  
 effects
Both products 
available for sale 
only from 
pharmacies under 
the supervision of a 
pharmacist
13.3 Factors that mediate and moderate harms associated with the use of OTC products 
13. Over-the-counter products
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14. Khat and Salvia divinorum
14.1 Acute adverse effects associated with the use of khat and Salvia divinorum
PHYSICAL
PSYCHOLOGICAL/PSYCHIATRIC
MORTALITY MORBIDITY
 • not documented, limited evidence base Khat
Acute complications
 • dry mouth
 • hyperthermia
 • sweating
 • aching
Cardiovascular complications
 • transient facial and conjunctival congestion
 • increased heart rate (tachycardia)
 • raised blood pressure
 • heart palpitations (extra-systoles)
 • myocardial insufficiency and cerebral   
 haemorrhage through stimulation of   
 adrenergic pathways
Gastrointestinal complications
 • constipation
Genitourinary complications
 • increased libido
Salvia divinorum
Acute complications
 • some users report experiencing physical and  
 mental tiredness 
 • flushed sensation
 • tachycardia
Khat
Personality/mood
 • insomnia
 • transient confusional states
Salvia divinorum
Organic/neurological
 • hallucinations
 • giddiness/dizziness
 • confusion/disorientation
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PHYSICAL
PSYCHOLOGICAL/PSYCHIATRIC DEPENDENCE/ WITHDRAWAL/ TOLERANCE
MORTALITY MORBIDITY
 • not documented, limited   
 evidence base
Khat
Cardiovascular complications
 • transient facial and conjunctival  
 congestion
 • increased heart rate and raised  
 blood pressure
 • heart palpitations (extra-systoles)
 • myocardial insufficiency and   
 cerebral haemorrhage through  
 stimulation of adrenergic   
 pathways
Gastrointestinal complications
 • brown staining of the teeth,   
 periodontal disease
 • inflammation of the mouth and  
 digestive system
 • anorectic effect and delayed   
 intestinal absorption; may   
 contribute to malnutrition
 • constipation – may lead to   
 laxative abuse
 • liver cirrhosis
Respiratory complications
 • increased prevalence of   
 respiratory diseases including   
 tuberculosis may be related to  
 secondary malnutrition and   
 heavy tobacco smoking
Reproductive disorders
 • limited evidence suggests that  
 khat chewing during pregnancy  
 may have an impact on foetal  
 growth and development; low  
 mean birth weights have been  
 reported in some studies
 • no published evidence that khat  
 causes teratogenic effects in   
 humans
 • limited evidence base for effects  
 on male reproductive health but  
 suggestion that use may be   
 associated with decreased fertility
Salvia divinorum
 • not documented
Khat
Personality/mood
 • anxiety
 • ‘mood swings’ (lability of mood)
 • nightmares
 • irritability, aggressive behaviour
 • psychotic phenomena
 • khat psychosis cases reported in  
 the literature; individuals had   
 recorded family histories of   
 psychotic disorders
Organic/neurological
 • cognitive dysfunction including  
 disturbed perceptual-visual   
 memory function
Salvia divinorum
 • not documented
Khat
Dependence 
 • limited evidence for a khat   
 dependence syndrome 
 • elements of ICD 10 stimulant  
 dependence have been described  
 among users including:  
– compulsive consumption   
– tolerance 
– borderline withdrawal   
 syndrome of tiredness, fine  
 tremors and nightmares   
– craving and the urge to seek  
 out khat are well known
Salvia divinorum
Dependence
 • limited evidence base but one  
 survey found little evidence of  
 dependence among users 
14.2 Chronic adverse effects associated with the use of khat and Salvia divinorum
14. Khat and Salvia divinorum
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ROUTE OF 
ADMINISTRATION/
DOSE
COMBINATION USE 
(CONCURRENT USE, 
CONSECUTIVE USE)
AVAILABILITY/ 
PURITY
SOCIAL CONTEXT/ 
SETTING
AGE/
DEVELOPMENTAL 
ISSUES
INDIVIDUAL 
VULNERABILITY LEGAL SITUATION
Khat
Route of 
administration
 • chewed
Salvia divinorum
Route of 
administration
 • user surveys  
 suggest smoking  
 is preferred route  
 of administration 
 • may also be  
 eaten fresh or  
 chewed and  
 vaporised, and  
 administered as a  
 tincture
Khat
Concurrent use
 • nicotine may be  
 commonly used  
 at the same time
Salvia divinorum
 • limited evidence  
 base
Khat
Availability
 • supplies largely  
 limited to areas  
 of high levels of  
 migrant   
 populations from  
 East Africa  
 – Somali, Yemen  
 and Ethiopian  
 communities
Salvia divinorum
Availability
 • perceived to be  
 easy to access  
 through internet  
 and head shops
Khat
Social context
 • tends to be used  
 in groups by men
 • suggestion that  
 social stigma  
 surrounding khat  
 use by women  
 means they may  
 be more likely to  
 use on their own  
 or in small  
 groups, or to  
 keep their use a  
 secret
 • not documented Khat
 • may contribute  
 to psychiatric  
 morbidity in  
 vulnerable  
 individuals
Khat plant and 
Salvia divinorum 
are not controlled 
under the Misuse 
of Drugs Act
Active ingredients 
of khat (cathinone 
and cathine) are 
Class C drugs
 
14.3 Factors that mediate and moderate harms associated with the use of khat and Salvia divinorum 
14. Khat and Salvia divinorum
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15. Prescription drugs*
15.1 Acute adverse effects associated with the use of prescription drugs
PHYSICAL
PSYCHOLOGICAL/PSYCHIATRIC
MORTALITY MORBIDITY
Benzodiazepines  and non-benzodiazepine 
hypnotics
Overdose
 • risk of coma, respiratory depression and death  
 associated with use in combination with   
 alcohol or other central nervous system   
 depressants (e.g. heroin)
CNS stimulants
Overdose
 • reports of fatal overdoses involving the use  
 of these drugs alone are rare
Benzodiazepines and non-benzodiazepine 
hypnotics
Acute complications 
 • no evidence to suggest acute risk from drug  
 itself – risk historically associated with route of  
 use (e.g. injection of temazepam)
 • risk of injury arising from sedative properties  
 of these drugs
CNS stimulants
Acute complications 
 • toxicity arising from methylphenidate and  
 dexamphetamine overdose similar to other  
 amphetamine-like drugs
 • minor effects commonly described following  
 cases of modafinil overdose include agitation,  
 anxiety and headache, and increased heart  
 rate
 • reported complications of intravenous abuse  
 of methylphenidate include retinopathy,   
 emphysema, medial medullary syndrome (a  
 rare type of stroke), hepatic dysfunction and  
 multiple organ system failure 
Benzodiazepines and non-benzodiazepine 
hypnotics
Organic/neurological
 • depress mental activity and altertness
 • memory loss/amnesia
Personality/mood
 • drowsiness
 • lethargy
 • disinhibition
 • chaotic paranoid behaviour
 • aggression, violent behaviour
CNS stimulants
Personality/mood
 • toxicity arising from methylphenidate and  
 dexamphetamine overdose similar to other  
 amphetamine-like drugs (e.g. agitation, panic)
 • concerns that modafinil use may be associated 
 with suicidal thoughts, mania and symptoms  
 of psychosis such as delusion
*Including benzodiazepines (temazepam, diazepam, nitrazepam and clonazepam), non-benzodiazepine hypnotics (zaleplon, zolpidem and zopiclone) and central nervous 
system (CNS) stimulants (dexamphetamine, methylphenidate and modafinil)
For prescription opioids see Table 12
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PHYSICAL
PSYCHOLOGICAL/PSYCHIATRIC DEPENDENCE/ WITHDRAWAL/ TOLERANCE
MORTALITY MORBIDITY
Benzodiazepines
Overdose
• low rates of mortality but   
 implicated in a significant   
 proportion of opioid overdose  
 fatalities and in combination with  
 alcohol
Non-benzodiazepine hypnotics and 
CNS stimulants
 • not documented
Benzodiazepines and non-
benzodiazepine hypnotics
Chronic complications
• no evidence to suggest chronic  
 risk from drug itself – risk   
 historically associated with route  
 of use (e.g. injection of   
 temazepam)
• limited evidence that exposure to  
 benzodiazepines in early   
 pregnancy is associated with an  
 increased risk of major   
 malformations and oral cleft
CNS stimulants
 • not documented
Benzodiazepines and non-
benzodiazepine hypnotics 
Organic/neurological
• loss of control over own   
 behaviour (loss of volitional   
 control)
Personality/mood
• depression
• anxiety
• attention deficit
CNS stimulants
Personality/mood
• not documented, but effects   
 likely to be similar to other   
 amphetamine-like drugs (e.g.  
 psychosis, repetitive behaviours,  
 paranoia)
Benzodiazepines
Dependence
 • good evidence for a   
 benzodiazepine  dependence   
 syndrome
 • can induce psychological   
 dependence without tolerance 
Withdrawal
 • convulsions – possibly fatal
 • rebound insomnia
 • dysphoria, anxiety, irritability,   
 depression, malaise
 • decreased concentration
 • muscle twitching, tremors
 • depersonalisation
 • nausea and vomiting
 • perceptual hypersensitivity/  
 distortions
 • headaches
Non-benzodiazepine hypnotics 
Dependence
 • rarely reported in the   
 international literature
Withdrawal
 • symptoms described following  
 long-term use include craving,  
 anxiety, and insomnia
CNS stimulants
Dependence
 • indication that methylphenidate  
 has a high abuse potential
 • abuse potential of modafinil may  
 be greater than thought
15.2 Chronic adverse effects associated with the use of prescription drugs
15. Prescription drugs
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ROUTE OF 
ADMINISTRATION/
DOSE
COMBINATION USE 
(CONCURRENT USE, 
CONSECUTIVE USE)
AVAILABILITY/ 
PURITY
SOCIAL CONTEXT/ 
SETTING
AGE/
DEVELOPMENTAL 
ISSUES
INDIVIDUAL 
VULNERABILITY LEGAL SITUATION
Benzodiazepines
Route of 
administration
 • risk historically  
 associated with  
 use by injection  
 – blocking of  
 peripheral veins  
 in arms, legs, skin  
 abscesses, deep  
 vein thrombosis
Non-
benzodiazepine 
hypnotics
Route of 
administration
 • orally,   
 intravenously or  
 by crushing or  
 snorting it
CNS stimulants
Route of 
administration
 • methylphenidate  
 and dexampheta- 
 mine used orally,  
 by injection, or  
 by snorting
 • injecting  
 complications  
 related to  
 insoluble  
 excipients in  
 tablets
Benzodiazepines
Concurrent use
 • in combination  
 with opioids  
 – increased risk  
 of drug use
 • use in   
 combination with  
 alcohol increases  
 the risk of  
 withdrawal fits,  
 which can be  
 fatal
 • opioid users may  
 use benzodiaz- 
 epines for their  
 pharmacological  
 effects and to  
 augment the  
 effects of weak  
 heroin
Non-
benzodiazepine 
hypnotics 
 • suggestion that  
 may be used by  
 drug users as a  
 replacement for  
 benzodiazepines
CNS stimulants
Concurrent use
 • US college  
 settings – reports  
 of combined use  
 of methylphen- 
 idate with alcohol 
 and/or cannabis
Benzodiazepines 
and non-
benzodiazepine 
hypnotics
Availability
 • long term  
 prescribing  
 increases risk of  
 dependence
 • dose related  
 factors
 • effective  
 importation  
 policies have  
 reduced  
 availability of  
 illegal imports
Benzodiazepines 
and non-
benzodiazepine 
hypnotics
Social context 
 • social use rare 
among long-term 
prescription users
CNS stimulants
Social context/
setting
 • methylphenidate  
 use has been  
 reported in US  
 college settings  
 to enhance  
 study, as well as  
 recreationally 
Benzodiazepines 
and non-
benzodiazepine 
hypnotics
Age 
• early use has  
 been noted in  
 some adolescent  
 groups, but this  
 has tended to be  
 localised
CNS stimulants
Age
• risk of serious  
 life-threatening  
 skin reactions  
 with modafinil in  
 children
Benzodiazepines
• overdose risk  
 may be enhanced 
  by concurrent  
 depressant drug  
 use
CNS stimulants
• higher risk of  
 abuse among  
 people with a  
 history of  
 substance abuse  
 or psychiatric  
 problems
Misuse of Drugs 
Act 1971
Class B
dexamphetamine, 
methylphenidate
Class C
benzodiazepines, 
zolpidem
Not controlled 
zopiclone, zaleplon, 
modafinil
 
15.3 Factors that mediate and moderate harms associated with the use of prescription drugs 
15. Prescription drugs
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16. Tobacco
16.1 Acute adverse effects associated with the use of tobacco
PHYSICAL
PSYCHOLOGICAL/PSYCHIATRIC
MORTALITY MORBIDITY
Death by nicotine poisoning
 • rare, occurs in children or non-smokers
Accidental death
 • can be caused by fires that may result from  
 smoking
Sympathetic over-activation
 • especially among novice users
 • palpitations
 • sweating
 • tremor
 • nausea
 • dizziness
Respiratory complications
 • irritant effects of smoke on respiratory system
Injury
 • injury resulting from fires
Oral tobacco use
Acute complications
 • irritant effects on site of absorption
Personality/mood
 • increased anxiety
 • mood disturbance
 • increased irritability during periods of enforced 
 abstinence
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PHYSICAL
PSYCHOLOGICAL/PSYCHIATRIC DEPENDENCE/ WITHDRAWAL/ TOLERANCE
MORTALITY MORBIDITY
Cardiovascular disease
• coronary heart disease
• peripheral vascular disease
• blood clots may form in the   
 arteries supplying the heart   
 (coronary thrombosis) or the   
 brain (cerebral thrombosis)   
 leading to a heart attack or stroke 
Cancers 
• lung
• digestive tract (mouth, tongue,  
 throat and oesophagus) 
Respiratory disease
• chronic obstructive pulmonary  
 disease, defined by a long-term  
 cough with mucus (chronic   
 bronchitis) and/or destruction of  
 the lungs over time (emphysema)
• death from slow and progressive  
 breathlessness
Accidents
• fires are an important cause of  
 accidental death that may result  
 from smoking
Exposure to second hand smoke
• coronary heart disease and lung  
 cancer among adults
Cancers strongly linked to smoking
• cancer of lung, mouth, pharynx,  
 larynx
• cancer of oesophagus, bladder,  
 kidney, pancreas
• cancer of stomach, liver, cervix,  
 nose, lip
Vascular complications
• chronic obstructive pulmonary  
 disease
• heart attack
• abdominal aortic aneurysm
• coronary artery disease
• peripheral vascular disease
• stroke
Other diseases/conditions
• pneumonia
• peptic ulcer
• periodontal disease
• osteoporosis
• macular degeneration, cataracts
Minor ailments
• decreased exercise tolerance
• weight loss
• bad breath (halitosis)
• increased susceptibility to coughs  
 and colds
• increased signs of ageing
Reproductive disorders
• decreased fertility in males and  
 females
• smoking in pregnancy associated  
 with increased risk of miscarriage,  
 perinatal mortality and low birth  
 weight
Exposure to second hand smoke
Among adults:
• lung cancer
• coronary heart disease
Among infants and children:
• infections of the lower respiratory  
 tract 
• middle ear disease
• major respiratory symptoms   
 (cough, phlegm, wheeze and   
 breathlessness)
• asthma
• reduced lung function
Association with mental health 
disorders
• strong association between   
 mental health disorders, including  
 schizophrenia and mood  
 disorders, and tobacco smoking
Significant risk factor for dementia
• Alzheimer's disease
• other types of dementias
• evidence of cognitive decline   
 among elderly smokers
Dependence
 • good evidence for a nicotine   
 dependence syndrome
 • nicotine is comparatively more  
 likely to cause dependence   
 among users than other   
 psychoactive substances   
 including  alcohol, heroin, cocaine 
 and cannabis
Withdrawal
 • craving for nicotine
 • anxiety
 • irritability
 • frequent changes in mood   
 (emotional lability)
 • inability to concentrate
 • insomnia
 • increased appetite
Tolerance
 • rapid development of tolerance  
 to adverse effects e.g. nausea
 • acute tolerance to effects on   
 heart rate
 • no tolerance to peripheral   
 vasoconstriction
 • acute tolerance to the subjective  
 sensations of nicotine (i.e. the  
 ‘pleasurable’ effects of smoking)
16.2 Chronic adverse effects associated with the use of tobacco
16. Tobacco
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ROUTE OF 
ADMINISTRATION/
DOSE
COMBINATION USE 
(CONCURRENT USE, 
CONSECUTIVE USE)
AVAILABILITY/ 
PURITY
SOCIAL CONTEXT/ 
SETTING
AGE/
DEVELOPMENTAL 
ISSUES
INDIVIDUAL 
VULNERABILITY LEGAL SITUATION
Route of 
administration
 • smoked
 • use of filters in  
 some cigarettes
 • increased  
 tobacco use in  
 pipes and roll-ups
 • varies as a  
 function of  
 intensity of  
 inhalation
Consecutive use
 • cigarette smoking 
 is a relapse risk in  
 drinkers
Availability
 • age limit of 18  
 on purchase
 • increased  
 availability and  
 reduced price  
 associated with  
 illegal importation  
 of illicit tobacco
Social context/
setting
 • smoking is  
 common among  
 opioid users 
 • frequent use  
 among drinkers
Age
• early onset of  
 smoking and  
 drinking clearly  
 linked to earlier  
 onset and more  
 regular use of  
 illicit drugs in  
 adolescents and  
 more difficulty in  
 quitting as an  
 adult
 • the stimulating  
 effects of  
 nicotine  on  
 cardiovascular  
 system can be  
 detrimental to  
 people with  
 cardiovascular or  
 respiratory  
 disease
Not controlled 
under Misuse of 
Drugs Act 1971
16.3 Factors that mediate and moderate harms associated with the use of tobacco
16. Tobacco
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17. Volatile substances*
PHYSICAL
PSYCHOLOGICAL/PSYCHIATRIC
MORTALITY MORBIDITY
Acute complications
 • toxicity varies greatly with the specific   
 substance and causes of fatalities are unclear
 • most fatalities involve physiological depression 
 of the central nervous system, accidents (falls,  
 drowning, fire) or sudden death related to  
 abnormal heart rhythms (cardiac arrhythmia)
 • may lose consciousness and die through  
 choking on own vomit
 • danger from suffocation if plastic bag placed  
 over head to inhale
 • intense cooling in mouth caused by squirting  
 lighter fuel down throat may result in   
 laryngeal spasm blocking airways and causing  
 death by asphyxiation, or by profound   
 slowing of the heart via vagal action
Acute intoxication
 • adverse effects vary greatly with the specific  
 substance and mode of administration
– flushed face and neck
– cold sweats
– loss of balance, unsteadiness and lack of  
 coordination
– fainting
– headache
– nausea, vomiting
– confusion, dizziness, disorientation
– tachycardia, palpitations
– drowsiness, sedation, unconsciousness
– risk of accidental injury while intoxicated
Personality/mood
 • confusional states, disorientation
 • distorted perceptions, delusions,   
 hallucinations, pseudo hallucinations
 • aggression, agitation and fear
17.1 Acute adverse effects associated with the use of over-the-counter (OTC) products
*Glues, thinners, aerosols, paints and lighter fuel
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PHYSICAL
PSYCHOLOGICAL/PSYCHIATRIC DEPENDENCE/ WITHDRAWAL/ TOLERANCE
MORTALITY MORBIDITY
 • not documented, limited   
 evidence base
Chronic complications
 • no consistent pattern – unclear  
 why some users are affected and  
 others are not
 • peripheral and central   
 neurological damage
 • kidney failure
 • liver toxicity
 • severe gastrointestinal upset
 • muscle damage
 • very long term (e.g. 10 years)  
 solvent misuse may result in   
 lasting impairment of brain   
 function (especially affecting   
 control of movement)
Pregnancy
 • use during pregnancy may   
 increase the risk of adverse   
 outcomes
 • suggestion that use may be   
 associated with a neonatal   
 withdrawal syndrome
Substance specific – petrol
Chronic complications
 • lead poisoning
Organic/neurological
 • decreased ability to concentrate
Personality/mood
 • insomnia
 • nightmares
Dependence
 • evidence that volatile substance  
 users experience signs and   
 symptoms of a dependence   
 syndrome is limited
Withdrawal
 • reports in the literature of a   
 withdrawal syndrome similar to  
 alcohol withdrawal
 • irritability, headaches
Tolerance
 • develops within 2 to 3 weeks of  
 persistent use but is lost after a  
 few days of abstinence
17.2 Chronic adverse effects associated with the use of volatile substances
17. Volatile substances
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ROUTE OF 
ADMINISTRATION/
DOSE
COMBINATION USE 
(CONCURRENT USE, 
CONSECUTIVE USE)
AVAILABILITY/ 
PURITY
SOCIAL CONTEXT/ 
SETTING
AGE/
DEVELOPMENTAL 
ISSUES*
INDIVIDUAL 
VULNERABILITY LEGAL SITUATION
Route of 
administration
 • inhaled
 • method of  
 placing plastic  
 bags completely  
 over the heads  
 increases risk of  
 suffocation
 • some substances  
 (e.g. butane)  
 may be sprayed  
 directly down the  
 throat – practice  
 has been  
 associated with  
 cases of sudden  
 death
Concurrent use
 • use with alcohol  
 and other central  
 nervous system  
 depressants will  
 bring increased  
 risk of   
 asphyxiation and  
 death
Availability
 • widely available  
 in the household  
 and shops  
 (newsagents,  
 chemists,  
 supermarkets)
 • commercially  
 available cans of  
 lighter fuel are  
 the most  
 common cause  
 of volatile  
 substance abuse  
 deaths
Setting
 • risk of injury  
 when consumed  
 alone in  
 potentially  
 dangerous  
 locations – e.g.  
 near water (risk  
 of drowning), on  
 a high building  
 (risk of falls)
 • risk of death  
 when consumed  
 alone – e.g. from  
 the consequences 
 of an abnormal  
 heart rhythm  
 (arrhythmia)
Age
• volatile   
 substances are  
 unique among  
 substances of  
 abuse as the  
 main abusers are  
 children and  
 adolescents  
 (aged 10 to 18  
 years)
 • behavioural  
 problems,  
 learning  
 difficulties
 • poor general  
 physical health
 • increased risk of  
 involvement with  
 problem alcohol  
 and tobacco use
Not controlled 
under Misuse of 
Drugs Act 1971
17.3 Factors that mediate and moderate harms associated with the use of volatile substances
17. Volatile substances
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PART THREE 
CROSS-CUTTING THEMES
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18. Adulterants in illict drugs*
18.1 Adulterants commonly identified in illicit drugs
ADULTERANT(S)/ 
LICIT USE
POTENTIAL REASON FOR  
PRESENCE AS ADULTERANT POTENTIAL PUBLIC HEATH RISKS
HEALTH EFFECTS ASSOCIATED WITH  
USE OF ADULTERATED ILLICIT DRUGS 
IDENTIFIED IN CASE REPORTS
Sucrose, lactose, 
dextrose and 
mannitol 
• sugars
• commonly used to dilute/add bulk to  
 heroin and cocaine
• legally and readily available
• inactive adulterants  • none reported
Lead
• soft, malleable   
 metal
Heroin
• potentially a by-product of the use of  
 lead pots in illicit heroin manufacture
Methamphetamine
• sometimes used in methamphetamine  
 manufacture; poor manufacturing can  
 result in lead residue in the drug  
 product
 • in low dosages lead poisoning can  
 have mild effects 
 • injecting illicit drugs adulterated with  
 lead causes severe adverse health  
 effects
Lead poisoning
Symptoms may include: 
 • abdominal pain and cramping 
 • headaches
 • anaemia
 • dizziness
 • nausea/vomiting
 • muscle weakness
 • convulsions
 • coma
 • kidney damage
 • damage to the central nervous system
Caffeine
• psychoactive   
 stimulant drug
Caffeine is legal, cheap and more readily 
available than illicit drugs.
Heroin
• vaporizes heroin at lower temperature  
 when smoked – slightly increases  
 efficiency
Cocaine, amphetamine, 
methamphetamine and ecstasy
• stimulant properties of caffeine can  
 create similar, although usually milder,  
 effects to stimulant drugs
 • in small doses there are few serious  
 health repercussions
 • moderate to large doses can cause  
 considerable harms (e.g. mood  
 disturbances, anxiety, sleep   
 disturbance)
 • none reported
Procaine
• local anaesthetic
Heroin
• facilitates smoking of heroin
• may relieve the pain of intravenous  
 injection due to anaesthetic properties
Cocaine
• similar anaesthetic and subjective  
 effects as cocaine
 • risk of toxicity at high doses (e.g.  
 nausea, vomiting, dizziness, tremors,  
 convulsions, anxiety)
 • none reported
Paracetamol
• over-the-counter   
 analgesic 
Paracetamol is legal, easily available and 
relatively cheap
Heroin
• analgesic effects and bitter taste of  
 paracetamol may disguise poor quality 
 heroin
• may be used because it has similar  
 melting point to heroin
 • low dosages should have minimal  
 impact
 • risk of liver toxicity at high doses
 • none reported
Strychnine
• pesticide
Fine motor stimulant; at low doses acts 
as a muscle stimulant
Heroin
• enables greater retention of heroin  
 when volatized (the process of  
 smoking heroin)
• has only been found at non-life  
 threatening quantities.
Cocaine
• reason for inclusion unknown – may  
 have been unintentional
 • has only been reported in non-life-  
 threatening quantities
 • small increases could potentially be  
 fatal
Strychnine poisoning
Symptoms may include:
 • muscle spasm
 • a form of spasm in which the head,  
 neck and spine are arched backwards  
 (opisthotonus)
*Tables 18.1 and 18.2 summarise the findings of an evidence-based overview of adulterants in illicit drugs (Cole et al., 2010), and their associated adverse health effects. 
It should be noted that adulterants in illicit drugs are predominantly substances which are legal, readily available, and likely to have minimal impact on users’ health at low 
dosages. However, the methods currently used to analyse illicit drug samples mean that it is not possible to determine how commonly adulterants are present in illicit drugs 
at doses likely to cause harm. 
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18.2 Adulterants identified in particular illicit drugs
18. Adulterants in illict drugs
ADULTERANT(S)/ 
LICIT USE
POTENTIAL REASON FOR  
PRESENCE AS ADULTERANT POTENTIAL PUBLIC HEATH RISKS
HEALTH EFFECTS ASSOCIATED WITH  
USE OF ADULTERATED ILLICIT DRUGS 
IDENTIFIED IN CASE REPORTS
Heroin
Phenobarbital 
• barbiturate
• psychoactive drug
• facilitates smoking of heroin
• risk of adverse effects and death from  
 large doses (e.g. disorders of the liver,  
 respiratory depression, mood   
 disturbances)
• may be life-threatening in injecting  
 drug users who are hypersensitive to  
 phenobarbital
 • none reported
Quinine
• antimalarial   
 medication
• bitter taste similar to heroin and may  
 be used as a diluents
• mimics the respiratory ‘rush’ felt by  
 injecting heroin users shortly after  
 administration 
 • adverse effects from large doses are  
 serious and may be life-threatening  
 (e.g. acute renal failure; cinchonism  
 including tinnitus, hearing impairment,  
 vertigo, vomiting, diarrhoea, visual  
 disturbances, confusion; muscle  
 weakness)
 • can also cause a host of other adverse  
 health reactions including acute  
 kidney failure, gastric disturbances  
 and cardiovascular complications
 • none reported
Clenbuterol
• asthma    
 decongestant and   
 bronchodilator drug
• reason for inclusion unknown
• may be related to unintentional  
 contamination 
 • can cause poisoning at moderate to  
 high dosages
 • low doses typically cause adverse  
 cardiovascular effects (e.g. increase in  
 heart rate, blood pressure)
• cardiovascular effects
• novel neuromuscular syndrome  
 characterised by muscle spasm and  
 overactive or overresponsive reflexes  
 (hyperreflexia)
Scopolamine
• anticholinergic   
 alkaloid
• colourless, odourless and tasteless
• not easily detectable
 • low doses cause sleepiness and  
 drowsiness 
 • high doses can cause euphoria
Anticholinergic toxicity
Complications include:
• blurred vision
• agitation
• fever
• urinary retention
• flushed skin
• dilated pupils
Cocaine
Local anaesthetics 
• e.g. lidocaine, 
benzocaine and 
procaine
• similar (stronger) anaesthetic effects  
 as cocaine
• gives the impression of higher quality  
 cocaine
 • adverse cardiovascular and central  
 nervous system reactions can occur at  
 low doses
 • adverse effects from a large dose(s) are  
 serious and may be life-threatening
 • increases the toxicity of cocaine
 • difficulty circulating oxygen through  
 the blood stream    
 (methaemoglobinaemia)
Phenacetin
• analgesic
• pain relieving properties 
• similar physical properties to cocaine
 • banned in many countries due to links  
 with kidney failure and suspected  
 carcinogenicity
 • difficulty circulating oxygen through  
 the blood stream    
 (methemoglobinaemia)
Levamisole
• medication to expel  
 parasitic worms   
 (anthelmintic)
• unknown – may give a more intense  
 high
 • generally no longer used in human  
 treatment, but still available as a  
 veterinary medicine
 • highly toxic
 • levamisole poisoning
 • fever 
 • lowered white blood cell count  
 (agranulocytosis)
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MDMA
Amphetamine, 
methamphetamine
•  illicit stimulant   
 drugs
• have similar properties to the   
 stimulant effects of MDMA/‘ecstasy’
• amphetamine substances are often  
 sold as, or in combination with,  
 MDMA
 • moderate doses can cause a range of  
 adverse health effects
 • adverse effects from a large dose(s)  
 are serious and may be life-threatening
 • none reported
PMMA, PMA
• synthetic drugs,   
 chemically   
 analogous to   
 MDMA
• unknown
• potentially to improve apparent  
 quality and increase weight
 • lack of evidence on the health  
 consequences, but suggestion that  
 may be more toxic than MDMA
 • high doses have caused death 
 • none reported
Cannabis
Aluminium
• soft, malleable   
 metal
• unknown
 • aluminium contamination may result  
 from impure water supply
 • contribute to smoking related diseases  • none reported
Glass • unknown
• potentially to improve apparent  
 quality and increase weight
 • health risks associated with the  
 inhalation of hot glass fumes
 • none reported
18.2 Adulterants identified in particular illicit drugs (continued)
18. Adulterants in illict drugs
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CHILDREN AND ADOLESCENTS OTHER ADULTS
Harms associated with substance use at an early age
 • onset of drug use in adolescent has been shown to be associated with  
 an excess risk of drug dependence soon after onset of drug use,  
 compared to onset in adulthood
Harms associated with early use of specific substances
Alcohol
 • a significant proportion of deaths among young people are related to  
 the acute consequences of alcohol consumption (e.g. road traffic  
 accidents)
 • use in early adolescence is a risk factor for drug use in later life
 • heavy drinking during adolescence may affect normal brain functioning 
 during adulthood
 • early age of drinking onset is associated with an increased likelihood of  
 developing alcohol abuse or dependence in adolescence and adulthood
Tobacco
 • early onset of smoking and drinking clearly linked to earlier onset and  
 more regular use of illicit drugs 
Anabolic agents
 • disruption of the normal pattern of growth and behavioural maturation  
 in adolescence (e.g. stunting of height; virilization)
Risk factors associated with substance use at an early age
 • having a parent or other family members who uses psychoactive  
 substances or alcohol – may be associated with problems in family  
 functioning or the effects of maternal substance use during pregnancy  
 on child development
 • early school leaving, school truancy, poor school performance and  
 expulsion or exclusion from school
 • involvement in crime
 • being in care
 • psychological problems
Alcohol
 • the majority of alcohol-related deaths occur among older age groups,  
 mostly from liver disease and cancers
 • evidence suggests that older adults are at a relatively high risk of  
 experiencing drinking problems
 • metabolic and physiological changes associated with ageing may lead  
 to harmful effects at lower levels of consumption than for younger  
 drinkers; may aggravate existing medical problems
 • risks of interaction between alcohol use and prescription drugs and  
 over-the-counter products
Prescription drugs and OTC products
 • frequent users of prescription drugs and OTC products
 • older women are more likely to be prescribed, and to misuse,   
 psychoactive medications than men
 • older women are at a higher risk of prescription drug misuse compared  
 to any other age group
 • misuse may be intentional or unintentional
Illicit drugs
 • prevalence of illicit drug use is increasing among older age groups as  
 current cohorts of drug users age
 • little is known about the longer term effects of recreational drug use
19.1 Age-related harm associated with substance use 
19. Age-related factors
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20. Gender-related factors
20.1 Gender-specific harms associated with substance use
ACROSS LICIT AND ILLICIT SUBSTANCES LICIT SUBSTANCES ILLICIT SUBSTANCES
 • in general, drug use is considerably more  
 common among men than women 
 • women generally report shorter progressions  
 from first drug use to dependence than men
 • women appear to be more sensitive to the  
 adverse effects of drugs than men
 • older women are at a higher risk of   
 prescription drug misuse compared to any  
 other age group
 • women with drug problems may suffer   
 disproportionately from a range of problems  
 and experience particularly high levels of  
 mental health problems
Alcohol
 • women are more sensitive to the physiological  
 effects of alcohol than men – achieve higher  
 blood concentrations, report feeling more  
 intoxicated and show higher vulnerability to  
 alcohol dependence
 • women may have a greater sensitivity to the  
 neurotoxic effects of alcohol
Tobacco
 • women are more likely than men to develop a  
 dependence on nicotine
 • women report shorter intervals between  
 cigarettes, and find it more difficult to quit  
 tobacco smoking than men
Amphetamines and cocaine
 • women may have a faster progression to  
 dependence than men
 • some differences in the use and effects of  
 cocaine have been reported between men  
 and women; evidence is limited
MDMA
 • women are more likely than men to   
 experience low sodium levels in the blood  
 caused by excessive ingestion of water   
 (hyponatraemia)
 • physical and/or psychological adverse effects  
 may be more frequent among women than  
 men (similar effects with cocaine) 
 • men may experience greater acute   
 physiological effects (e.g. effects on blood  
 pressure, heart rate and body temperature)  
 compared with females
Cannabis
 • compared to men, women may experience  
 quicker progression to cannabis dependence  
 and treatment entry
Opioids
 • some studies of heroin users indicate that  
 women tend to escalate their use of heroin  
 more rapidly, become addicted in a shorter  
 period of time, and seek treatment earlier  
 than men do
 • excess mortality among female opioid users in  
 comparison with the general female   
 population is higher than the corresponding  
 figure for males
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20.2 Complications and harms associated with substance use in pregnancy
20. Gender-related factors
LICIT DRUGS ILLICIT DRUGS
Alcohol
 • spontaneous abortion
 • still birth
 • preterm delivery and decrease in length of gestation
 • decreased foetal growth and birth weight
 • Fetal Alcohol Spectrum Disorder
Tobacco
 • marginally increased risk for spontaneous abortion
 • contributes to a condition where the placenta remains in the  
 lower portion of the uterus in later stages of pregnancy  
 (placenta praevia) and placental abruption
 • low birth weight
 • premature birth 
 • perinatal mortality is increased as a result of these effects
Licit opioids
 • animal studies have shown adverse effects of tramadol on the  
 foetus
Cannabis
 • like tobacco, cannabis use in pregnancy may be harmful to foetal development;  
 studies show a consistent association between cannabis use in pregnancy and  
 reduced birth weight – though less so than as a result of tobacco smoking during 
 pregnancy 
 • some reports that children born to women who have used cannabis in   
 pregnancy may face mild developmental problems; however, the evidence is  
 mixed and confounded by the other situational, health and lifestyle factors and  
 polysubstance use in this population e.g. cannabis users are more likely to use  
 tobacco, alcohol and other illicit drugs during pregnancy
Cocaine
 • premature rupture of the membranes and placental abruption associated with  
 cocaine use in pregnancy
 • other adverse effects attributed to cocaine may be caused by the other   
 confounding situational, health and lifestyle factors and polysubstance use in this 
 population
Amphetamines
 • use in pregnancy has been associated with low birth weight, prematurity and  
 increased foetal morbidity – confounded by the other situational, health and  
 lifestyle factors and polydrug use in this population
Anabolic agents
 • anabolic-androgenic steroids are teratogenic – use of these and other anabolic  
 agents are contraindicated in pregnancy
Illicit opioids
 • intrauterine growth of the foetus may be inhibited
 • newborns exposed to illicit opioids may have  low birth weight compared to  
 non-exposed children, be born prematurely, and experience respiratory   
 depression and withdrawal symptoms – these symptoms may contribute to the  
 increased risk of perinatal mortality associated with use of illicit opioids in  
 pregnancy 
 • evidence for a direct effect of illicit opioids is confounded by other situational,  
 health and lifestyle factors (e.g. use of other drugs, mother’s nutritional status,  
 lifestyle, infections and exposure to trauma) are at least as decisive for the  
 outcome of the pregnancy
 • problems with neurological developments may also arise as a consequence of a  
 deprived social environment
Plants 
 • limited evidence suggests that khat chewing during pregnancy may have an  
 impact on foetal growth and development; low mean birth weights have been  
 reported in some studies
 • no published evidence that khat causes teratogenic effects in humans
Volatile substances 
 • use during pregnancy may increase the risk of adverse outcomes
 • suggestion that use may be associated with a neonatal withdrawal syndrome
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21.1 Harms associated with injecting drug use 
21. Route of administration
INFECTIOUS COMPLICATIONS EMBOLI, BLOOD VESSEL OCCLUSION AND THROMBOSIS OTHER HARMS SUBSTANCE-SPECIFIC HARMS
Systemic infections
 • Viral infections
 • HIV
 • hepatitis B
 • hepatitis C 
Bacterial and fungal infections
 • bacteria in the bloodstream (bacterial   
 septicaemia)
 • infection of the heart valves and/or   
 endocardium (endocarditis)
 • inflammation of a joint (septic arthritis)
 • infection of the bones (osteomyelitis)
Skin and injection site infections 
Common presentations:
 • collection of pus with associated swelling  
 and inflammation (abscesses)
 • skin infection caused by bacteria (cellulitis)
More severe local infections may include:
 • cervical abscesses
 • advanced soft tissue infection (necrotising  
 fasciitis)
 • bacterial infections causing death of muscle  
 tissue (myonecrosis)
 • infected ulcers as a consequence of impaired  
 blood flow
Bacterial and fungal infections
 • staphylococcus aureus is the most commonly 
 identified cause of skin infections
 • serious harms including life-threatening soft  
 tissue infection and death have resulted from  
 outbreaks of infection with clostridium   
 novyi, other clostridium species (including  
 clostridium botulinum) and bacillus   
 anthracis
 • use of lemon juice to prepare heroin for   
 injection has been implicated as the cause of  
 outbreaks of fungal infections related to the  
 Candida species, including serious eye   
 infections (endophthalmitis)
Increased risk of infection arises from:
 • injecting in areas of skin with high   
 populations of commensal bacteria
 • subcutaneous and intramuscular injections
Impurities and non-soluble 
excipients may become 
microemboli in blood causing:
 • small clumps of dead cells to  
 form (granulomas) in the  
 lung leading to breathing  
 difficulties (dyspnoea), lack of  
 oxygen (hypoxia), pulmonary  
 hypertension or emphysema
 • damage to the retina – cases  
 associated with the injection  
 of methylphenidate have  
 been described  
Certain risk factors increase the 
chance of venous blockage:
 • inflammation of the vein  
 (phlebitis)
 • injecting into the groin
 • lack of exercise
 • smoking
 • taking oral contraceptives
Overdose risk 
 • injecting drug use poses  
 particular risks for overdose 
 • allows for the almost instant  
 absorption of large quantities  
 of the drug from the  
 bloodstream 
Irritant effects
 • irritant reactions at injecting  
 sites (e.g. phlebitis) can be  
 attributed to:
– some drugs e.g.  
 temazepam – may  
 directly cause abscesses,  
 tissue necrosis, venous  
 fibrosis, inflammation of  
 veins (phlebitis)
– adulterants e.g. quinine
– poor injection technique
– acidic substances used to  
 aid dilution
– more likely to occur with  
 subcutaneous injection or  
 via the accidental  
 administration of drugs  
 to the surrounding tissues  
 on intravenous injection  
 (extravasation)
Intra-arterial injection irritant 
substances or those containing 
solid particles
 • swelling distal to the injection  
 site
 • pain
 • discolouration
 • sensory and/or motor deficit
Air embolus
 • potential hazard associated  
 with the intravenous injection  
 of large volumes of drugs
Anabolic agents
 • intramuscular injection may  
 result in damage to the  
 injection site and surrounding  
 structures
Cocaine
 • has local anaesthetic  
 properties which may mask  
 the pain of impending  
 damage
 • effects of cocaine by injection  
 are relatively brief and  
 therefore users may inject  
 frequently increasing  
 likelihood of sharing and  
 blood borne virus exposure
Crack cocaine
 • is not soluble without the  
 addition of a weak acid (e.g.  
 citric acid)
 • increased risk of infection  
 associated with the use of  
 lemon juice as an acidifier
 • increased risk of tissue  
 damage and possibly  
 anaerobic infections is  
 associated with the excess  
 use of acidifiers
Prescription drugs
 • injecting complications  
 related to insoluble excipients  
 in tablets; including blockage  
 of blood vessels, formation of  
 blood clots, and arterial  
 inflammation 
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21. Route of administration
21.2 Harms associated with drug use orally, intranasally or by inhalation
ORAL USE  
(SWALLOWING)
INTRANASAL USE  
(SNORTING)
INHALATION USE  
(INHALATION/SMOKING) SUBSTANCE-SPECIFIC HARMS
• oral route may be preferred for  
 convenience (e.g. MDMA, LSD  
 and alcohol)
• nearly all drugs can be taken   
 orally, but many drugs are   
 absorbed unpredictably via this  
 route
• tends to be the route least   
 associated with harmful   
 consequences as psychoactive  
 effects can take longer to   
 develop and/or may be less   
 intense
 • impaired breathing
 • minor nosebleeds
 • irritation and possible perforation  
 of nasal septum
 • ulceration of nasal mucosa
 • vasoconstriction of mucous   
 membranes and subsequent   
 vasodilation sometimes causing  
 chronic inflammation of the   
 mucous membrane of the nose  
 (rhinitis)
 • dental erosion if substance is   
 snorted through the nose and  
 then enters the mouth;   
 associated with cocaine and   
 methamphetamine use
Inhalation
 • irritation and rash around nose  
 and mouth from directly inhaled  
 substances
Smoking
 • respiratory complaints e.g.   
 coughing, wheezing, chest pain,  
 black sputum, lung damage
 • may exacerbate existing   
 respiratory illnesses such as   
 asthma
 • increased risk of respiratory   
 cancers associated with tobacco  
 use
Anabolic agents
 • acute liver injury associated with  
 use of 17α-alkylated oral AAS
Cocaine
 • local anaesthetic effect resulting  
 in difficulty swallowing
Cannabis
 • differences in the administration  
 (i.e. compared to tobacco   
 smoking) mean smoking cannabis 
 may result in greater harm to the  
 respiratory system
 • oral consumption makes dosage  
 difficult to regulate – unpleasant  
 reactions more difficult to avoid
Heroin
 • rare reports of a disease of the  
 white matter of the brain   
 (leukoencephalopathy)  
 associated with smoking heroin
Volatile substances
 • intense cooling in mouth/throat  
 may cause laryngeal spasm   
 blocking airways and causing   
 subsequent death by   
 asphyxiation
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EFFECTS ASSOCIATED WITH CONCURRENT USE OF:
ALCOHOL ILLICIT DRUGS
Amphetamines • increases perceived total intoxication
• increases adverse cardiovascular effects
Cocaine
• limited evidence; may have adverse consequences   
 on the central nervous system
MDMA and related analogues • reduces subjective sedation associated with alcohol,  
 but not alcohol-induced impairments
• increase in plasma levels of MDMA
• decrease in blood alcohol levels 
• may enhance the temporary impairment of immune  
 cells associated with MDMA use (transient immune  
 dysfunction)
Cannabis
• users may potentially experience cumulative CNS   
 impairment
• may increase susceptibility to infection
Cocaine
• evidence from animal studies suggests an increased  
 risk of neurotoxicity
Anabolic agents  • none documented Cocaine
• potential for clenbuterol and AAS to exacerbate the   
 adverse cardiovascular effects of cocaine
Cannabis • reduction in driving performance
Cocaine  • increases blood levels of cocaine and the active   
 metabolite cocaethylene; users may perceive a more  
 intense feeling of intoxication
• users may perceive a reduction in the sedating   
 effects of alcohol 
• combination potentially increases adverse   
 cardiovascular effects
• patients with coronary artery disease or alcohol   
 dependence may be particularly vulnerable to the   
 combined toxic effects of alcohol and cocaine
Ketamine
• potential to exacerbate the cardiovascular risks of   
 cocaine (crack)
Methadone
• increases adverse cardiovascular effects (e.g.   
 increased blood pressure and heart rate) 
GHB • increases the risk of respiratory depression  • none documented
Nitrites  • none documented Misuse of drugs for treating erectile dysfunction (e.g. 
viagra)
• increases the hypotensive effects (abnormally low   
 blood pressure)
Opioids • increases the depressant effects of alcohol on the   
 central nervous system; can be fatal
• acute use of alcohol and methadone appears to   
 result in lower blood-alcohol levels – clinical   
 significance unclear
Benzodiazepines
• increase the depressant effects of opioids on the   
 central nervous system
Prescription drug misuse Benzodiazepines
• increase the depressant effects of alcohol on the   
 central nervous system
• diazepam increases plasma levels of alcohol
• may increase  aggression and/or amnesia
• may reduce the anxiety reducing (anxiolytic) effects  
 of benzodiazepines
CNS stimulants
• increases methylphenidate levels and exacerbates   
 effects on the central nervous system
22.1 Harms associated with the concurrent use of specific substances
22. Polysubstance use
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